UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED: DECEMBER 31, ~~2024~~2025

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM ____________ TO ____________

COMMISSION FILE NUMBER: 000-27781

UNITED HEALTH PRODUCTS, INC.

(Exact name of Registrant as specified in its charter)

Nevada		84-1517723
(State of jurisdiction of incorporation or organization)		(I.R.S. Employee Identification Number)

520 Fellowship Road, Suite #D-406 Mt. Laurel, NJ		08054
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (475) 755-1005

Securities registered pursuant to Section 12 (b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
None		None		None

Securities registered pursuant to Section 12 (g) of the Act: Common Stock, $0.001 Par Value

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Check whether the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes ☐ No ☒

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive data file required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Indicate by check mark whether the registrant has ﬁled a report on and attestation to its management’s assessment of the eﬀectiveness of its internal control over ﬁnancial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting ﬁrm that prepared or issued its audit report. ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of June 30, ~~2024~~2025, the number of shares held by non-affiliates was approximately ~~243~~257,~~814~~333,~~822~~222 shares. The approximate market value based on the last sale (i.e. $0.~~165~~098 per share as of June 30, ~~2024~~2025, the last business day of the second quarter) of the Company’s Common Stock was approximately $4025,~~229~~218,~~446~~657.

The number of shares issued and outstanding of the Registrant’s Common Stock, as of April ~~March 26~~14, ~~2025~~2026 was ~~252~~258,~~408~~690,~~222~~253.

United Health Products, Inc.

Annual Report on Form 10-K

For the Year Ended December 31, ~~2024~~2025

TABLE OF CONTENTS

Part I		Page
Item 1	Business	4
Item 1A	Risk Factors	89
Item 1B	Unresolved Staff Comments	1416
Item 1C	Cybersecurity	1517
Item 2	Properties	1517
Item 3	Legal Proceedings	1517
Item 4	Mine Safety Disclosures	1517
Part II
Item 5	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	1618
Item 6	[Reserved]	1820
Item 7	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1820
Item 7A	Quantitative and Qualitative Disclosures about Market Risk	2123
Item 8	Financial Statements and Supplementary Data	F-1
Item 9	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	2224
Item 9A	Controls and Procedures	2224
Item 9B	Other Information	2325
Item 9C	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	2325
Part III
Item 10	Directors, Executive Officers and Corporate Governance	2426
Item 11	Executive Compensation Discussion and Analysis	2830
Item 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	3032
Item 13	Certain Relationships and Related Transactions and Director Independence	3234
Item 14	Principal Accounting Fees and Services	3335
Part IV
Item 15	Exhibits and Financial Statement Schedules	3436
Signatures		3638

Table of Contents

Forward-Looking Statements

Statements in this annual report on Form 10-K that are not historical facts constitute forward-looking statements which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Those factors include, among other things, those listed under “Risk Factors” and elsewhere in this annual report. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Moreover, neither we nor any other person assumes responsibility.

Table of Contents

PART I

ITEM 1. BUSINESS

Company Overview

United Health Products, Inc. (“UHP”, “we” or the “Company”) develops, manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. Our gauze product, CelluSTAT®, is derived from cotton and designed to absorb exudate/drainage from superficial wounds and help control bleeding. We are in the process of seeking regulatory approval to sell our hemostatic gauze product line into the U.S. Class III and European CE Mark human surgical markets.

Developments

FDA Updates

We are continuing on our path to seek FDA Premarket Approval (PMA) for our CelluSTAT Hemostatic Gauze products to implement our business strategy.

In March 2024, we submitted a full application for Premarket Approval to the FDA. The FDA responded in June 2024 with a “Deficiencies Letter” listing approximately 40 specific comments and requests for additional information covering the device description, sterility & shelf life, clinical & performance testing, and biocompatibility sections of the PMA application. In August 2024, we submitted a Submission Issue Request (SIR) to the FDA outlining our plan to address and respond to the FDA’s comments. Then, in August 2024, at the FDA’s request, the Company followed-up with a condensed list of questions relating to the prior SIR submission.

InFrom September 23 through October 4, 2024, the ~~Company and~~ FDA conducted a ~~virtual~~Bioresearch ~~meeting~~Monitoring toProgram ~~discuss the SIR and the follow-up questions. During the discussion, the Company noted the results of its 2019 clinical trial involving 232 patients~~ (~~of whom 118 were treated with its hemostatic gauze~~BIMO) ~~that~~Inspection ~~showed~~of ~~statistically~~our ~~superior~~records ~~performance~~and inprocedures ~~time~~relating to ~~hemostasis~~our ~~using~~2019 ~~CelluSTAT~~clinical ~~over Ethicon’s Surgicel Original, the standard of care. The~~ study ~~results also showed no evidence of heterogeneity of results across procedure categories~~, ~~surgeons,~~following orwhich ~~clinical sites, indicating both poolability and generalizability of study results. The Company also noted that none of~~ the ~~adverse~~FDA ~~events~~delivered ~~that~~its ~~occurred~~Inspectional ~~during~~Observations ~~the~~on ~~study~~Form ~~were attributable to its hemostatic gauze product~~483.

~~Notwithstanding~~In ~~the~~October ~~safety~~2024, ~~record from~~ the ~~original~~Company ~~clinical~~and ~~study, the~~ FDA ~~requested~~conducted ~~more~~a ~~data~~virtual meeting to ~~confirm~~discuss the ~~safety~~Deficiencies Letter and ~~effectiveness~~our offollow-up ~~CelluSTAT~~questions. inDuring ~~surgical~~the ~~procedures~~discussion, inthe Company noted the ~~intestinal~~results ~~and~~of ~~thoracic~~its ~~organ~~2019 ~~space,~~clinical ~~where~~trial ~~organ~~involving ~~movement~~232 ~~can~~patients ~~impact~~(of ~~the~~whom ~~post~~118 ~~operative~~were ~~stability~~treated ofwith aits ~~hemostat~~hemostatic ~~and~~gauze) ~~where~~that ~~observation~~showed ofstatistically ~~post~~superior ~~operative~~performance ~~rebleeding~~in istime ~~more~~to ~~difficult.~~hemostasis Tousing ~~address~~CelluSTAT ~~this~~over ~~concern,~~Ethicon’s weSurgicel ~~have~~Original, ~~proposed~~the tostandard ~~enroll~~of 27care. ~~human~~The ~~subjects~~study inresults aalso ~~multi-site~~showed ~~study~~no asevidence anof ~~extension~~heterogeneity of ~~the~~results ~~original~~across ~~pivotal~~procedure ~~study~~categories, ~~with~~surgeons, ~~patients~~or ~~undergoing~~clinical ~~open~~sites, ~~surgical~~indicating ~~procedures~~both ~~within~~poolability ~~the~~and ~~organ~~generalizability ~~space~~of study results. The ~~supplemental~~Company ~~study~~also ~~process~~noted ~~will~~that ~~consist~~none of ~~submitting~~the anadverse ~~Investigational~~events ~~Device~~that ~~Exemption~~occurred ~~(IDE)~~during ~~for~~the ~~FDA~~study ~~approval,~~were ~~identifying~~attributable ~~and~~to ~~contracting~~its ~~suitable~~hemostatic ~~surgical~~gauze ~~sites, enrolling patents, and data collection and analysis~~product.

~~The~~Notwithstanding ~~FDA's~~the ~~180-day~~safety ~~PMA~~record ~~application~~from ~~review~~the ~~period~~original isclinical onstudy, ~~pause~~the ~~while~~FDA werequested ~~work~~more data to ~~address~~confirm the safety and effectiveness of CelluSTAT in surgical procedures in the intestinal and thoracic organ space, where the FDA’s ~~requests~~was concerned that organ movement could impact the post-operative stability of a hemostat and ~~will~~where ~~resume~~observation ~~once~~of wepost ~~submit~~operative ~~all~~rebleeding ~~our~~is ~~responses~~more difficult. To address this concern, we have proposed conducting a supplemental study, with patients undergoing open surgical procedures within the intestinal and thoracic organ space.

~~From~~On ~~September~~October 2325, ~~through~~2024, ~~October~~we 4submitted our response to the FDA’s observations. On March 24, ~~2024~~2025, the FDA ~~conducted~~issued a ~~Bioresearch~~Warning ~~Monitoring~~Letter ~~Program~~that ~~(BIMO)~~described ~~Inspection~~five violations of ~~our~~applicable ~~records~~regulations that occurred during the planning and ~~procedures~~execution ~~relating~~of tothe ~~our~~2018-19 clinical study,. ~~following~~These ~~which~~violations included: 1) failure to submit an IDE application to the FDA ~~delivered~~and ~~its~~failure ~~Inspectional~~to ~~Observations~~obtain onFDA ~~Form~~approval ~~483.~~prior Onto ~~October~~beginning ~~25,~~an ~~2024~~investigation for which FDA’s approval is required, we2) ~~submitted~~failure ~~our~~to ~~response~~ensure proper monitoring of the investigation, 3) failure to monitor and ensure clinical investigators’ compliance with the ~~FDA~~study protocol and failure to terminate investigator’s ~~observations,~~participation ~~which~~in the ~~FDA~~study ~~will~~following ~~consider~~non-compliance, in4) ~~developing~~failure ~~its~~to ~~final~~immediately conduct an evaluation of any unanticipated adverse device effects and failure to report onresults of such an evaluation to the ~~BIMO~~FDA ~~Inspection~~and to the appropriate IRB, and 5) failure to maintain accurate, complete, and current device shipment and disposition records.

~~There~~4 ~~can~~Table beof ~~no assurance that our PMA application will be approved.~~Contents

In response to the Warning Letter we conducted an analysis and investigation into root causes of these violations and developed Corrective and Preventative Actions (CAPAs) to address them, which we submitted to the FDA on April 14, 2025. In addition, we engaged an external monitor to review certain of the clinical data gathering during the clinical trial to report on the accuracy and reliability of the data, which we also submitted to the FDA in June and September 2025.

On December 10, 2025, the FDA issued a CAPA Assessment Letter that provided feedback on our response to the Warning Letter and our proposed CAPAs to address the violations that occurred during the 2019 study. In the letter, the FDA sought additional detail surrounding the Company’s 2018 correspondence with the WCG Institutional Review Board (IRB) regarding its approval of our clinical study, specifically relating to the FDA’s findings that the Company had modified certain FDA correspondence that it had presented to the IRB. In addition, FDA recommended that UHP conduct an audit of our processes, procedures and personnel (both internal and outside consultants) to ensure that the Company is able to ensure good clinical practices (GCP) when conducting a clinical study.

On January 5, 2026 we submitted to the FDA revised CAPAs and a proposal to conduct the recommended GCP Audit, and on February 16, 2026 submitted a report on our investigation of the 2018 IRB communications and a proposal for a third party monitor of our communications with the FDA and any IRB going forward to ensure the accuracy and regulatory compliance in these communications. On March 4, 2026 we held a Submission Issue Request (“SIR”) videoconference with the FDA to confirm their approval of our proposed collaboration with an established hemostatic device company wherein this company could serve as substitute Sponsor in a new pivotal IDE study of our CelluSTAT product, which the FDA did approve. On March 6, 2026, the FDA communicated their approval of the external audit firm that we had proposed on February 16 to conduct a GCP Audit of our procedures, process and personnel. This audit is expected to be completed by the end of July, 2026.

The timing to resolve the FDA Warning Letter is uncertain and we may not proceed with the clinical study requested by the FDA until its resolution. However, we are in discussions with the FDA and with potential corporate partners regarding a collaboration that would allow a partner to serve as substitute Sponsor of a CelluSTAT study, with UHP having an exclusive Rights to Reference to the study data for inclusion in a future PMA application. This plan would allow the study to be conducted concurrently with our ongoing efforts to resolve the Warning Letter, including the above mentioned GCP Audit.

There can be no assurance that our planned PMA application will be approved.

Financing with Alumni Capital

On December 16, 2025, the Company entered into a Securities Purchase Agreement with Alumni Capital LP (“Alumni”), pursuant to which Alumni provided a loan to the Company in the amount of $289,267 on a 15% original discount basis, evidenced by a senior convertible promissory note (the “Note”). The Company received net proceeds of $250,000. The Note bears no interest and matures on December 31, 2026. Subject to the terms of the Note, Alumni may convert the outstanding principal and accrued interest into shares of the Company’s common stock at a conversion price of $0.06039 per share. Alumni has agreed to limit its beneficial ownership of the Company’s common stock to less than 9.99% of the Company’s outstanding shares. In connection with the transaction, the Company entered into a registration rights agreement requiring the Company to register the resale of shares underlying the Note.

On the same date, the Company also entered into an Any Market Purchase Agreement (“AMPA”) with Alumni. Under the AMPA, the Company has the right, but not the obligation, to sell to Alumni up to an aggregate of $4,000,000 in value of the Company’s common stock from time to time through December 31, 2027, subject to the terms and conditions of the agreement. The purchase price of shares sold under the AMPA is based on a discount to the volume-weighted average price of the Company’s common stock over a specified trading period prior to each purchase notice. In connection with the AMPA, the Company issued Alumni a five-year warrant to purchase up to 3,484,321 shares of the Company’s common stock at an exercise price of $0.07462 per share.

On January 15, 2026, the Company filed a Registration Statement on Form S-1 with the Securities and Exchange Commission to register the resale of shares of the Company’s common stock issuable under the Note and the AMPA. The SEC declared the Registration Statement effective on January 30, 2026.

Our CelluSTAT Gauze Products

CelluSTAT Hemostatic Gauze (formerly branded as HemoStyp) is a natural substance created from chemically treated cellulose derived from cotton. It is an effective hemostatic agent registered with the FDA for superficial use under a 510(k) approval obtained in 2012 to help control bleeding from open wounds and body cavities. The CelluSTAT hemostatic material contains no chemical additives, thrombin, collagen or animal-derived products, and is hypoallergenic. When the product comes in contact with blood it expands slightly and quickly converts to a translucent gel that subsequently breaks down into cellulose and salts. Because of its benign impact on body tissue and the fact that it degrades to non-toxic end products, CelluSTAT does not impede the healing of body tissue as compared to certain competing hemostatic products.

CelluSTAT hemostatic gauze is a flexible, silk-like material that is applied by placing the gauze onto the bleeding tissue. The supple material can be easily folded and manipulated as needed to fit the size of the wound or incision. In surface bleeding and surgical situations, the product quickly converts to a translucent gel that allows the physician or surgeon to monitor the coagulation process. The gel maintains a neutral pH level, which avoids damaging the surrounding tissue. In superficial bleeding situations, CelluSTAT can be bonded to an adhesive plastic bandage or integrated into a traditional gauze component to address a broad range of needs, including traumatic bleeding injuries and prolonged bleeding following hemodialysis.

45 Table of Contents

Potential Target Markets

Our CelluSTAT material is currently cut to several sizes and configurations. While we have paused our commercial activities to focus on our Class III PMA application, our potential customer base includes, without limitation, the following:

	·	Hospitals and Surgery Centers for all Internal Surgical usage (in the event we obtain FDA Class III approval)
	·	Hospitals, Clinics and Physicians for external trauma
	·	EMS, Fire Departments and other First Responders
	·	Military Medical Care Providers
	·	Hemodialysis centers
	·	Nursing Homes and Assisted Living Facilities
	·	Dental and Oral & Maxillofacial Surgery Offices
	·	Veterinary hospitals

Primary Strategy

Our CelluSTAT technology received an FDA 510(k) approval in 2012 for use in external or superficial bleeding situations and we believe there is an opportunity for CelluSTAT products to address unmet needs in several medical applications that represent attractive commercial opportunities. However, the Class III human surgical markets, both domestic and international, represent the most attractive market for our products due to the smaller number of competitors offering Class III approved hemostatic agents and the resulting premium pricing for products that can meet the demanding requirements of the human surgical environment. We believe that our extensive laboratory testing and our completed human trial indicate that the CelluSTAT technology could successfully compete against established Class III market participants, and could gain a significant market share. As described above, we are in the process of seeking FDA pre-market approval for our CelluSTAT product. There can be no assurance that an FDA PMA will be granted.

In anticipation of receiving a Class III PMA (which cannot be assured), we are evaluating paths to rapidly develop and grow our revenue and profits in all target market segments, with the objective of maximizing shareholder value. We do not intend to pursue the full commercialization of our products independently nor to remain an independent company in the long term. Options under consideration include (i) a sale or merger of the Company with an industry leader in the wound care and surgical device sectors, which may include a pre-sale collaboration on commercialization and distribution and (ii) one or more commercial partnerships with established market participants, without any specific, associated sale or merger transaction.

56 Table of Contents

The Company has been contacted by several medical technology companies that are active in the surgical equipment and hemostatic products sectors, and who have expressed an interest in the Company’s products and business strategy. We continue to evaluate the potential commercial partnerships in anticipation of an FDA decision on our Class III PMA application. No assurances can be given that the Company will identify any commercialization candidate(s) or enter into a transaction.

Manufacturing and Packaging of our Products

The Company’s products will be manufactured to our specifications through a contract manufacturing arrangement with an FDA certified supplier that maintains stringent quality control protocols to assure the uniformity and quality of all of our gauze products. Information on the manufacturing process and our manufacturer’s facility has been submitted as part of our PMA submission. Our gauze products are cut to size, packaged and sterilized by service providers in the United States.

Patents and Trademarks

Our hemostatic gauze technology is protected through patents granted by the U.S. Patent and Trademark Office, which protection currently runs through 2029.

The Company has registered trademarks and trademark applications for the following product formats:

	·	BooBoo Strips
	·	HEMOSTYP
	·	The Ultimate Bandage
	·	Hemostrip
	·	CelluSTAT
	·	Nik Fix

Competition

The wound care products market in the United States is concentrated among large and established companies such as Baxter International, Becton Dickinson & Company, Johnson & Johnson (Ethicon), Teleflex and 3M Company, each of which have greater capital and operational resources than uswe do. Our hemostatic gauze product will directly compete in the hemostat and wound care markets served by these companies. In these markets, competitive factors include product performance, price, breadth of product offerings, value-added service programs, service and delivery, credit terms, and customer support.

67 Table of Contents

Government Regulation

We are subject to oversight by various federal and state governmental entities and we are subject to, and affected by, a variety of federal and state laws, regulations and policies generally applicable to the healthcare and medical device industries. See Item 1A “Risk Factors – Risks Relating to Government Regulation – ‘We are subject to extensive regulation by the FDA and must comply with the regulations of the FDA (including after the potential receipt of an FDA PMA), as well as state, local and applicable international regulations. Failure to do so could harm our business’; ‘The healthcare industry is subject to extensive government regulation, which can result in increased costs, delays, limits on its operating flexibility and competitive disadvantages’; and ‘Failure to comply with laws or government regulations could result in penalties’”.

Environmental Matters

The Company may be subject to, or affected by, environmental legislation including, among others, the Toxic Substances Control Act, the Clean Air Act, the Clean Water Act, Compensation and Liability Act (CERCLA or Superfund) and the Resource Conservation and Recovery Act. There may be laws and regulations that exist or that may come to pass that may also have an impact on the Company in ways that we cannot foresee. Compliance with the multitude of regulations issued by federal, state, provincial and local administrative agencies that may apply to the Company can be burdensome and costly. To date, the Company has not been impacted by these laws and regulations.

Research and Development Expenditures

In the years ending December 31, ~~2024~~2025 and ~~2023~~2024 we incurred research and development expenditures of $~~355~~269,~~936~~867 and $~~598~~355,~~810~~936, respectively.

Personnel

As of ~~March~~April 2615, ~~2025~~2026, we have ~~three~~two Company personnel working under full-time consulting agreements and engage certain external consultants as needed on an hourly basis for regulatory and other areas of expertise.

78 Table of Contents

ITEM 1A. RISK FACTORS

We are engaged in the development, sale and distribution of hemostatic gauze products to stop superficial bleeding. As we develop our business, there are numerous and varied risks, known and unknown, that may prevent us from achieving our goals. If any of these risks actually occur, our business, financial condition or results of operation may be materially adversely affected. In such case, the trading price of our common stock could decline, and investors could lose all or part of their investment.

RISKS RELATED TO OUR BUSINESS

We have a history of operating losses and we may continue to lose money in the future.

For the years ended December 31, ~~2024~~2025 and ~~2023~~2024, the Company had a net loss of $2,~~001~~669,~~733~~348 and $2,~~623~~001,~~267~~733, respectively. We may continue to lose money in the future, and we will rely on financing to fund our business strategy for the foreseeable future as discussed in the Risk Factor “We will need additional financing to execute our business plan and fund operations, which may not be available”.

We can provide no assurances that the FDA will approve our Class III application for internal surgical procedures in the U.S. market for our CelluSTAT product.

We are reliant on receiving Premarket Approval (PMA) from the FDA for our CelluSTAT product in order to implement our business strategy of targeting the surgical market. If we do not obtain a PMA for our CelluSTAT product, we will have to materially change our strategy, which we cannot assure we would be successful in doing. We filed our initial PMA application with the FDA in 2021, and after addressing FDA comments in the ensuing years following the COVID pandemic, we submitted our revised PMA application to the FDA in March 2024. The FDA responded, notifying us of certain ~~deficiencies~~violations inrelating ~~our~~to ~~application,~~the ~~which~~conduct weof ~~responded~~our to2019 clinical study and ~~discussed~~other ~~with~~deficiencies ~~the~~in ~~FDA~~our ~~during~~PMA ~~2024~~application, ~~and~~ which we continue to address. See Item 1 “Business – Developments”.

We cannot be assured that our CelluSTAT product will meet the FDA requirements for Premarket Approval or that we will ever receive the requisite PMA to be able to commercialize our CelluSTAT product in the U.S. human surgical market.

No assurances can be given that our plans to penetrate certain market segments will be successful.

We continue to believe that the Class III surgical markets, both domestic and international, represent the most attractive market for our products due to the limited competition from other Class III approved Oxidized Regenerated Cellulose (ORC) products and the resulting premium pricing for hemostatic agents that can meet the demanding requirements of the human surgical environment. As of the filing date of this Form 10-K, the FDA review process is ongoing ~~and we are preparing to submit an application for CE Mark approval in order to access the European and other markets~~. In the event we receive Class III ~~and CE Mark~~ approvals, which cannot be assured, we are evaluating the best paths to grow our revenue and profits in all potential markets, which could include one or more commercial partnerships and licensing agreements with established market participants or an acquisition/merger agreement with any such participants, each as an alternative to raising the necessary capital to establish and grow our own marketing and distribution capabilities via organic growth. We will carefully evaluate the returns on investment to create shareholder value of each of these strategies. No assurances can be given that our plans to penetrate all market segments or be acquired/merged with an established market participant will be successful on terms satisfactory to us, if at all.

We can provide no assurances that ongoing discussions with potential commercial partners and acquirers will result in the occurrence of a specific transaction.

The Company has been contacted by several medical technology companies that are active in the surgical equipment and hemostatic products sectors, and who have expressed an interest in the Company’s products and business strategy. In response to these inbound contacts, and to maximize shareholder value, the Company continues to consider a range of strategic alternatives, which include, without limitation, entering into one or more commercial and distribution partnerships, a sale of the Company or a standalone growth plan. There can be no assurances that any specific transaction will occur as a result of these discussions. No assurances can be given that the Company will identify a suitable acquisition or commercialization partnership candidate(s) or complete any transaction on terms that are in the best interests of shareholders.

89 Table of Contents

We will need additional financing to execute our business plan and fund operations, which may not be available.

We currently have a working capital deficit, minimal cash and limited sales of our products. As a result of the Company’s financial position, we may not be able to execute our current business plan and fund business operations long enough to achieve profitability. Our ultimate success will depend upon our ability to raise additional capital. There can be no assurance that additional funds will be available when needed from any source or, if available, will be on terms that are acceptable to us.

We will pursue required additional capital through various means, including commercial collaborations and debt or equity financings. Future financings through equity investments are likely to be dilutive to existing shareholders. Also, the terms of securities we may issue in future capital transactions may be more favorable for our new investors. Newly issued securities may include preferences, superior voting rights, the issuance of warrants or other derivative securities. The issuances of incentive awards under existing and future employee incentive plans, may have additional dilutive effects. Further, we may incur substantial costs in pursuing future capital raising and/or financing, including investment banking fees, legal fees, accounting fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection with certain securities we may issue, such as convertible notes and warrants, which may adversely impact our financial condition.

Our ability to obtain needed financing may be impaired by such factors as capital markets disruptions, both generally and specifically relating to the healthcare industry, and events that have a negative impact on existing and potential investors or funding sources. If the amount of capital we are able to raise from financing activities, together with our revenues from operations, is not sufficient to satisfy our capital needs we may be required to cease operations. See Item 1 “Business – Developments” for a discussion about our current financing by Alumni Capital.

No guarantee of market acceptance of our CelluSTAT Hemostatic Gauze.

Our success is dependent on market acceptance of our hemostatic gauze products. We cannot be certain that healthcare professionals and purchasing decision makers will conclude that our products offer a superior performance or value proposition, in any or all of the target markets we have identified, or that we will attain the level of market acceptance necessary to generate adequate revenues to cover our business costs and generate a return for investors.

We may be dependent upon commercial relationships to conduct our operations and implement our strategy.

Our proposed strategy includes the use of distribution and commercial partnerships to market and sell our hemostatic gauze products. We currently do not have any such commercial relationships. We may not be able to establish these relationships, or if established, we may not be able to maintain them. In addition, the dynamics of our relationships with strategic partners may require us to incur expenses or undertake activities we would not otherwise be inclined to in order to fulfill our obligations to these partners or maintain our relationships. If these relationships are not established or maintained, our business prospects may be limited, which could diminish our ability to conduct our operations. We can provide no assurances that distribution agreements will be entered into on terms satisfactory to us, if at all, or that our operations will be profitable as a result of these distribution agreements.

910 Table of Contents

We could experience difficulties in our supply chain.

Our ~~neutralized, oxidized,~~ regenerated cellulose ~~(“NORC”)~~ products are manufactured in Asia and packaged and sterilized in the United States to our specifications. Unforeseen events at any manufacturing or packaging location may result in a disruption of ~~production~~deliveries that could negatively impact our ability to supply our customers and generate revenues. ~~We own certain specialized production equipment which is installed at our contract-manufacturer’s location which is not readily available should we need to replace it.~~ While we intend to maintain significant supplies of finished product inventory, any prolonged disruption at one of our ~~manufacturer~~manufacturers’s ~~facility~~facilities could have a material adverse impact on our operations and business..

We are currently dependent on one hemostatic gauze product to generate income in the future.

The Company’s hemostatic gauze products are currently our sole source of potential revenue in the future. While we have multiple formats of this product and hope to access new markets upon receipt of a Class III PMA, we cannot provide assurance that our product will be accepted by potential customers or that new, superior hemostatic technologies will not be introduced that negatively impact the market perceptions of our own products. Unless we are able to develop or acquire additional product lines, the failure to develop a commercial market for this product line will materially adversely affect our operations.

Our business may suffer if we do not attract and retain talented personnel.

Our success will depend in large measure on the abilities, expertise, judgment, discretion, integrity and good faith of our management and other personnel in conducting our intended business. In addition, we depend on management and strategic consultants to correctly interpret and respond to market data, economic and other conditions to locate and adopt appropriate business opportunities. WeCurrently, ~~presently~~our ~~have~~management aconsists ~~small~~solely ~~management~~of ~~team~~our Chief Executive Officer, ~~which~~who is also serving as our acting Chief Financial Officer. As a result, we ~~intend~~are tohighly ~~expand~~dependent inon ~~conjunction~~the ~~with~~continued service and performance of a single individual, and the loss, incapacity or unavailability of this individual could have a material adverse effect on our ~~planned~~business, financial condition and results of operations. In addition, the concentration of management responsibilities in one individual may result in limited internal controls, reduced segregation of duties, and ~~growth~~increased operational risk. We intend to ensure that management and any key personnel are appropriately compensated; however, their continued service to the Company cannot be guaranteed. If we are unable to attract and retain additional key management personnel and enter into satisfactory employment and other agreements, our business may be adversely affected.

We may not be able to adequately protect our technologies or intellectual property rights.

Our ability to achieve commercial or strategic success will depend in part on maintaining patent protection and trade secret protection of our technologies as well as successfully defending our intellectual property against third-party challenges. We will only be able to protect our technologies from unauthorized use by third parties to the extent that valid and enforceable patents or trade secrets cover them. Furthermore, the degree of future protection of our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. Additionally, legal enforcement of intellectual property rights is costly and we may not have the financial resources to take the necessary legal action to protect our rights.

If our intellectual property positions are challenged, invalidated, circumvented, or expire, or if we fail to prevail in future intellectual property litigation, our business could be adversely affected. We have created multiple variations of our gauze product and will protect each of these new generation platforms and product with additional intellectual property. Our success depends in part on our ability to defend our intellectual property rights. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and often involve complex legal, scientific, and factual questions. Third parties may seek to challenge, invalidate, or circumvent our intellectual property rights. In addition, our patent positions might not protect us against competitors with similar products or technologies because competing products or technologies may not infringe our patents. Also, there are third parties who have patents or pending patent applications that they may claim necessitate payment of a royalty or prevent us from commercializing our patent in certain territories. Patent disputes are frequent, costly and can preclude, delay, or increase the cost of commercialization of products.

1011 Table of Contents

We have identified various material weaknesses in our internal control over financial reporting which could affect our ability to timely and accurately report our results of operations and financial condition. These material weaknesses may not have been fully remediated as of the filing date of this report and we cannot assure you that other material weaknesses will not be identified in the future.

Our Chief Executive Officer ~~and~~has ~~Principal Financial Officer have~~ concluded that, as of December 31, ~~2024~~2025, we had material weaknesses in our internal controls over financial reporting and that, as a result, our disclosure controls and procedures and our internal controls over financial reporting were not effective at such date. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting that creates a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

In addition, we believe that we continued to have material weaknesses in our internal control over financial reporting subsequent to December 31, ~~2024~~2025. See “Controls and Procedures” under Item 9A for a detailed discussion of the material weaknesses identified as of December 31, ~~2024~~2025 and possible material weaknesses as of subsequent periods. Although we are in the process of implementing remedial measures to address all of the identified material weaknesses, our assessment of the impact of these measures has not been completed as of the filing date of this report, and we cannot assure you that these measures will be adequate. Moreover, we cannot assure you that additional material weaknesses in our internal control over financial reporting will not arise or be identified in the future.

As a result, we must continue to improve our operational, information technology, and financial systems, infrastructure, procedures, and controls, as well as continue to expand, train, retain, and manage our employee base. Any failure to do so, or any difficulties we encounter during implementation, could result in additional material weaknesses or in material misstatements in our financial statements. These misstatements could result in a future restatement of our financial statements, could cause us to fail to meet our reporting obligations, or could cause investors to lose confidence in our reported financial information, leading to a decline in our stock price.

Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. This could make it more difficult for us to raise funds and adversely affect our relationships with creditors, investors and suppliers.

Our auditors believe that substantial doubt exists regarding our ability to remain in business. We cannot provide any assurance that we will in fact operate our business profitably or obtain sufficient financing to sustain our business in the event we are not successful in our efforts to generate sufficient revenue and operating cash flow. The expression of such doubt by our independent registered public accounting firm or our inability to overcome the factors leading to such doubt could have a material adverse effect on our relationships with prospective customers, creditors, investors and suppliers, and therefore could have a material adverse effect on our business.

1112 Table of Contents

RISKS RELATED TO GOVERNMENT REGULATION

We are subject to extensive regulation by the FDA and must comply with the regulations of the FDA (including after the potential receipt of an FDA PMA), as well as state, local and applicable international regulations. Failure to do so could harm our business.

Our CelluSTAT products are subject to extensive regulation by the FDA. These regulations relate to manufacturing, labeling, sale, promotion, distribution and shipping. Before a new medical device, or a new intended use of a legally marketed device, can be marketed in the United States, it must be cleared or approved by the FDA through the applicable 510(k) premarket notification submission, granting of a de novo request, or Premarket Approval (PMA)), unless an exemption applies. The clearance and approval process is expensive, time-consuming, and uncertain. Failure to comply with applicable regulatory requirements of the FDA can result in an enforcement action, which could include a variety of sanctions, including fines, injunctions, civil penalties, recall or seizure of our products, operating restrictions, partial suspension, or total shutdown of production and criminal prosecution. The FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, that may prevent or delay approval or clearance of our products or impact our ability to modify our products after clearance on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain clearance for our products, increase the costs of compliance or restrict our ability to maintain products after clearance.

The FDA has substantial discretion in the PMA approval process. The FDA can limit or deny approval of a product for many reasons, including, but not limited, to:

	·	a product may not be deemed to be safe and effective;

	·	the FDA may not find the data from clinical trials and preclinical studies sufficient;

	·	the opportunity for bias in the clinical trials as a result of the open-label design may not be adequately handled and may cause our trial to fail;

	·	the FDA may not approve suppliers’ processes or facilities; or

	·	the FDA may change its approval policies or adopt new regulations.

In addition, regulatory clearance or approval by the FDA does not ensure registration, clearance, approval, or certification by comparable foreign regulatory authorities. Complying with foreign regulatory requirements, including obtaining registrations, clearances, approvals, or certifications, can be expensive and time consuming, and we may not receive regulatory clearances, approvals, or certifications in each country or region in which we plan to market our products or we may be unable to do so on a timely basis. In turn, this could limit our ability to expand into international markets, which could have a material adverse effect on our business, financial condition, and results of operations. See Item 1 “Business – Developments” for a discussion about our FDA PMA process

The healthcare industry is subject to extensive government regulation, which can result in increased costs, delays, limits on its operating flexibility and competitive disadvantages.

The healthcare industry is generally subject to extensive regulatory requirements. Adhering to these requirements generally carries significant costs to industry participants, including our Company. Given our limited financial resources, these significant costs may adversely affect our business and financial results. If we are unable to pass on these costs through our product pricing they would negatively impact our profit margin.

Table of Contents

Healthcare insurance legislation may lead to unintended adverse effects for businesses involved in our industry. New legislation that gives the Federal government greater regulatory powers may lead to negative consequences for certain aspects of our business. The full scope of the ongoing uncertainty in healthcare related legislation may not be known for several years, making it difficult to predict the future consequences that would create challenges to our Company, or if we can overcome them.

Failure to comply with laws or government regulations could result in penalties.

Certain government requirements for technologies in the healthcare market may require licensure or mandatory minimum standards relating to the provision of products and services. Failure to comply with these requirements could materially affect our ability to expand into new or existing markets. Future regulatory developments may also cause disruptions to our operations.

GENERAL RISK FACTORS

We are subject to the reporting requirements of the federal securities laws, which can be expensive.

We are a public reporting company and, accordingly, subject to the information and reporting requirements of the Exchange Act and other federal and state securities laws, including compliance with the Sarbanes-Oxley Act of 2002. The costs of preparing and filing annual and quarterly reports, proxy statements and other information with the SEC and furnishing audited reports to stockholders significantly increase our operating costs.

It is time consuming, difficult and costly for us to develop and implement the internal controls and reporting procedures required by the Sarbanes-Oxley Act. We may need to hire additional financial reporting, internal controls and other finance personnel in order to develop and implement appropriate internal controls and reporting procedures. If we are unable to comply with the internal control’s requirements of the Sarbanes-Oxley Act, we may not be able to obtain the independent accountant certifications required by that Act.

1214 Table of Contents

Public company compliance requirements may make it more difficult to attract and retain officers and directors.

The Sarbanes-Oxley Act and rules subsequently implemented by the SEC have required changes in corporate governance practices of public companies. Compliance with the new rules and regulations increases our operating costs and makes certain activities more time consuming and costly than if we were not a public company. As a public company, these new rules and regulations make it more difficult and expensive for us to obtain director and officer liability insurance. As a result, it may be more difficult for us to attract and retain qualified persons to serve on our Board of Directors or as executive officers.

There exist risks to stockholders relating to dilution: authorization of additional securities and reduction of percentage share ownership following investment.

To the extent that additional shares of common stock are issued, our existing stockholders would experience dilution of their respective ownership interests in the Company. Additionally, if the Company issues a substantial number of shares of common stock in connection with or following an investment, a change in control of the Company may occur which may affect, among other things, the Company’s ability to utilize net operating loss carry forwards, if any. Furthermore, the issuance of a substantial number of shares of common stock may adversely affect prevailing market prices for our common stock and could impair the Company’s ability to raise additional capital through the sale of its equity securities. The Company has in the past and may in the future compensate certain consultants and other service providers using our shares of common stock, which would result in further dilution for our existing stockholders.

Our stock price may be volatile.

The market price of our common stock is likely to be highly volatile and could fluctuate widely in response to various factors, many of which are beyond our control, including the following:

	·	changes in the healthcare industry;
	·	competitive pricing pressures;
	·	our ability to obtain working capital financing;
	·	additions or departures of key personnel;
	·	our ability to execute our business plan;
	·	operating results that fall short of expectations;
	·	loss of certain material strategic relationships;
	·	regulatory developments;
	·	economic and other external factors, including among others, effects on the markets; and
	·	period-to-period fluctuations in our financial results.

In addition, the securities markets have from time-to-time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.

We have not paid dividends in the past and do not expect to pay dividends in the future. Any return on investment may be limited to changes in the value of our common stock.

We have never paid cash dividends on our common stock and do not anticipate doing so in the foreseeable future. The payment of cash dividends on our common stock will depend on earnings, financial condition and other business and economic factors affecting us at such time as our board of directors may consider relevant. If we do not pay dividends, return on investment will only occur if our stock price appreciates.

1315 Table of Contents

There is currently no established market for our common stock, and we cannot ensure that one will ever develop or be sustained.

The Company’s common stock is quoted on the ~~OTC Pink~~OTCQB. Management considers the market for our common stock to be limited. We can provide no assurances that an established trading market for our common stock will exist in the future.

Our common stock is deemed a “penny stock”, which may make it more difficult for our investors to sell their shares.

Our common stock is subject to the “penny stock” rules adopted under Section 15(g) of the Securities Exchange Act of 1934. The penny stock rules apply to companies whose common stock is not listed on a national securities exchange and trades at less than $5.00 per share or that have tangible net worth of less than $5,000,000 ($2,000,000 if the company has been operating for three or more years). These rules require, among other things, that brokers who trade penny stock to persons other than “established customers” complete certain documentation, make suitability inquiries of investors and provide investors with certain information concerning trading in the security, including a risk disclosure document and quote information under certain circumstances. Many brokers have decided not to trade penny stocks because of the requirements of the penny stock rules and, as a result, the number of broker-dealers willing to act as market makers in such securities is limited. If we remain subject to the penny stock rules for any significant period, it could have an adverse effect on the market, if any, for our securities. Inasmuch as our securities are subject to the penny stock rules, investors may find it more difficult to dispose of our securities.

Offers or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.

If certain of our stockholders seek to sell substantial amounts of our common stock in the public market upon the expiration of any holding period under Rule 144, or expiration of lock-up periods applicable to outstanding shares, or issued upon the exercise of outstanding options or warrants, it could create a circumstance commonly referred to as an “overhang” and in anticipation of which the market price of our common stock could fall. The existence of an overhang, whether or not sales have occurred or are occurring, also could impair our ability to raise additional financing through the sale of equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None

1416 Table of Contents

ITEM 1C. CYBERSECURITY

Since 2018 the Company has been primarily focused on pursuing FDA Pre-Market Approval (PMA) for its CelluSTAT products to enable it to access the Class III surgical markets and has de-emphasized its commercial operations. We have fewer than 10 employees and consultants and currently use third-party vendors and service providers for certain product development and regulatory approval activities. Most of the information generated and collected by the Company is stored and maintained by these third-party vendors and service providers. Each of these providers has demonstrated its own cybersecurity protocols which our management believes to be adequate for protecting the Company’s digital files in their possession. Our CEO (who is also one of the Company’s directors) ~~and~~is ~~VP of Finance are~~ responsible for assessing and managing cybersecurity risks. ~~Neither~~Our ofCEO ~~them~~does not have cybersecurity expertise. Due to the current small size and limited commercial operations of the Company, we have no formal cybersecurity policies and processes in place, however, the Board and management believe cybersecurity represents an important component of the Company’s overall approach to risk management and oversight.

Cybersecurity threats have not materially affected, and are not reasonably likely to affect, the Company, including its business strategy, results of operations or financial condition while we are strategically focused on pursuing FDA ~~PMA~~Premarket ~~approval~~Approval and have minimal commercial operations. The Company is not aware of any material security breach to date. Accordingly, the Company has not incurred any expenses over the last two years relating to information security breaches. The occurrence of cyber-incidents, or a deficiency in our cybersecurity or in those of any of our third-party service providers could negatively impact our business by causing a disruption to our operations, a compromise or corruption of our confidential information and systems, or damage to our business relationships or reputation, all of which could negatively impact our business and results of operations. There can be no assurance that the Company's third-party vendors’ and service providers’ cybersecurity risk management processes, including their policies, controls or procedures, will be effective in protecting the Company’s systems and information.

ITEM 2. PROPERTIES

Since May 2023, the Company has leased approximately 1,800 square feet of office space in Mt. Laurel, New Jersey that is used as the principal executive office.

The Company is a virtual company with personnel in ~~three~~two states, largely working remotely.

ITEM 3. LEGAL PROCEEDINGS

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

1517 Table of Contents

PART II

Market information

The common shares of the Company are quoted on the ~~OTC~~OTCQB ~~Pink~~ under the symbol UEEC. There is no established trading market for our common shares and there has been only limited trading activity to date. The following table sets forth the high and low sales price of the common stock on a quarterly basis for the periods presented, rounded to the nearest penny.

	High		Low
For Year Ended 2025
First Quarter	$	0.28	$	0.05
Second Quarter	$	0.28	$	0.09
Third Quarter	$	0.11	$	0.06
Fourth Quarter	$	0.09	$	0.04
For Year Ended 2024
First Quarter	$	0.25	$	0.18
Second Quarter	$	0.21	$	0.15
Third Quarter	$	0.19	$	0.11
Fourth Quarter	$	0.15	$	0.05
For Year Ended 2023
First Quarter	$	0.30	$	0.19
Second Quarter	$	0.34	$	0.17
Third Quarter	$	0.34	$	0.23
Fourth Quarter	$	0.29	$	0.20

Holders

As of ~~March~~April 2615, ~~2025~~2026, there were approximately ~~408~~415 holders of record of the Company’s issued and outstanding shares of common stock.

Dividends

The Company has not paid any dividends to date, has not yet generated earnings sufficient to pay dividends, and currently does not intend to pay dividends in the foreseeable future.

1618 Table of Contents

Stock Issuances

The following table summarizes all sales and issuances by the Company of unregistered securities during the year ended December 31, ~~2024~~2025. The securities in the below-referenced transactions were (i) issued without registration and (ii) were subject to restrictions under the Securities Act and the securities laws of certain states, in reliance on the private offering exemptions contained in Sections 4(a)(2), 4(a)(6) and/or 3(b) of the Securities Act and on Regulation D promulgated under the Securities Act, and in reliance on similar exemptions under applicable state laws as transactions not involving a public offering. No placement or underwriting fees were paid in connection with these transactions. All cash proceeds from the sale of securities were used for working capital and general corporate purposes.

Date of Sale	Title of Security	Number Sold	Consideration Received	Purchaser/Recipient
January 2024	Common Stock	600,000	$122,627 in cash	White Lion (1)
July 2025	Common Stock	600,000	$47,814 in cash	White Lion (1)
February 2024	Common Stock	850,000	$164,973 in cash	White Lion (1)
August 2025	Common Stock	200,000	$15,494 in cash	White Lion (1)
March 2024	Common Stock	600,000	$103,625 in cash	White Lion (1)
April 2024	Common Stock	1,100,000	$183,082 in cash	White Lion (1)
May 2024	Common Stock	150,000	$22,032 in cash	White Lion (1)
June 2024	Common Stock	150,000	$20,476 in cash	White Lion (1)
August 2024	Common Stock	500,000	$71,616 in cash	White Lion (2)
September 2024	Common Stock	900,000	$123,210 in cash	White Lion (2)
October 2024	Common Stock	450,000	$40,539 in cash	White Lion (2)
December 2, 2024	Unit	700,000	$56,000 in cash	Accredited investor (3)
December 3, 2024	Unit	125,000	$10,000 in cash	Accredited investor (3)

	(1)	Issued by the Company to White Lion Capital, LLC pursuant to the terms of the Common Stock Purchase Agreement dated September 1, 2022, as amended January 25, 2023.
	(2)	Issued by the Company to White Lion Capital, LLC pursuant to the terms of the Common Stock Purchase Agreement dated September 1, 2022, as amended June 20, 2024.
	(3)	Issued to accredited investors pursuant to subscription agreements and warrant agreements dated as shown above. Each Unit consists of 1 share of common stock and ½ warrant to purchase an additional share at $0.14/share until December 31, 2026.

(1)

Issued by the Company to White Lion Capital, LLC pursuant to the terms of the Common Stock Purchase Agreement dated September 1, 2022, as amended June 20, 2024.

Description of Our Capital Stock

The following description of our capital stock is a summary only and is qualified by reference to our Certificate of Incorporation and Bylaws, which are included as Exhibits 3.1, 3.2, 3.3 and 3.4 to this report.

General

Our authorized capital stock consists of (i) 300,000,000 shares of common stock, with a par value of $0.001 per share and (ii) 1,000,000 shares of Series A preferred stock with par value of $0.001. As of ~~March~~April 2614, ~~2025~~2026, there were ~~252~~258,~~408~~690,~~222~~253 shares of common stock and no shares of Series A preferred stock issued and outstanding.

Common Stock

Each holder of Common Stock will be entitled to one vote for each share of Common Stock held of record by such holder with respect to all matters to be voted on or consented to by our stockholders, except as may otherwise be required by applicable Nevada law. The stockholders will not have pre-emptive rights under our Certificate of Incorporation to acquire additional shares of Common Stock or other securities. The Common Stock will not be subject to redemption rights and will carry no subscription or conversion rights. In the event of liquidation of the Company, the stockholders will be entitled to share in corporate assets on a pro rata basis after the Company satisfies all liabilities and after provision is made for each class of capital stock having preference over the Common Stock (if any). Subject to the laws of the State of Nevada, and the rights of the holders of any outstanding series of preferred stock (if any), the Board of Directors will determine, in their discretion, to declare dividends advisable and payable to the holders of outstanding shares of Common Stock.

1719 Table of Contents

Transfer Agent and Registrar

Pacific Stock Transfer Company is the registrar and transfer agent for our shares of common stock. Its address is 6725 Via Austi Pkwy, Suite 300, Las Vegas, NV 89119, United States; Telephone: (800) 785-7782.

ITEM 6. [RESERVED]

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion and analysis contain forward-looking statements that involve risks, uncertainties and assumptions. The actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited to, those set forth under ‘Risk Factors’ and elsewhere in this Annual Report on Form 10-K.

Executive Level Overview

The Company develops, manufactures, and markets CelluSTAT®, the Company’s patented hemostatic gauze designed to absorb exudate and help control bleeding from superficial wounds. Made from cotton, our gauze provides an effective solution for wound care and hemostasis in various healthcare settings.

The Company is actively working to expand our market reach by securing regulatory approvals for use in human surgical applications. It is in the process of seeking U.S. Class III approval from the Food and Drug Administration (FDA) and CE Mark certification in Europe. These approvals would allow the Company to introduce its hemostatic gauze product line into the surgical market, where the Company’s management believes it can make a meaningful impact on patient care.

See Item 1 “Business – Developments” for a discussion about the Company’s efforts in seeking FDA Premarket Approval for its CelluSTAT product.

Results of Operations years ending December 31, ~~2024~~2025 and ~~2023~~2024

The following table sets forth a summary of certain key financial information for the years ended December 31, ~~2024~~2025 and ~~2023~~2024:

	2024			2023
	2025			2024
Revenue	$	-		$	-
Gross profit	$	-		$	-
Operating (expenses)	$	(2,~~007~~255,~~572~~474	)	$	(2,~~426~~007,~~539~~572	)
Operating (loss)	$	(2,~~007~~255,~~572~~474	)	$	(2,~~426~~007,~~539~~572	)
Other income (expense)	$	5(413,~~839~~874	)	$	~~(196~~5,~~728~~839	)
Net (loss)	$	(2,~~001~~669,~~733~~348	)	$	(2,~~623~~001,~~267~~733	)
Basic and diluted	$	(0.01	)	$	(0.01	)

1820 Table of Contents

Year ended December 31, ~~2024~~2025 versus year ended December 31, ~~2023~~2024

During the year ended December 31, ~~2024~~2025 and ~~2023~~2024, the Company had $0 revenues, respectively. The Company did not generate any revenues in the current year due to the continued focus of the Company’s capital and resources towards obtaining a Class III PMA.

Operating Expenses

Total operating expenses for the year ended December 31, ~~2024~~2025 and ~~2023~~2024 were $2,~~007~~255,~~572~~474 and $2,~~426~~007,~~539~~572, respectively.

The ~~decrease~~increase in operating expenses was primarily due to aan ~~decrease~~increase of $~~462~~745,~~500~~125 in ~~litigation~~stock-based ~~settlement~~compensation ~~expenses,~~offset by a decrease of approximately $~~126~~494,~~407~~750 in ~~legal and~~ professional expenses. ~~and~~The aincrease ~~decrease of $242,874~~ in ~~research~~stock-based ~~and~~compensation ~~development~~is ~~expenses~~due ~~during~~to the ~~year~~vesting ~~ended~~of ~~December 31~~4,725,000 ~~2024~~RSUs ~~offset~~and byrecording ~~an increase of~~ $~~375~~1,~~000~~120,125 inas stock-based compensation. ~~expense~~The ~~related~~decrease toin ~~the~~professional ~~vesting~~expenses ofis ~~RSU’s~~due ~~and~~to anthe ~~increase~~Company ofterminating ~~$33,598~~services ~~for~~with ~~the~~certain ~~write-down of obsolete inventory~~consultants.

Other income (expense)

Other income (expense) for the year ended December 31, ~~2024~~2025 and ~~2023~~2024 was $5(413,~~839~~874) and $~~(196~~5,~~728)~~839, respectively. The change in other income (expense) was ~~primarily~~ due to ~~the~~an ~~Company~~increase ~~having~~in a loss on fraud of $~~115~~242,~~085~~000, ~~gain~~an onincrease ~~settlement~~in interest expense of ~~debt~~$90,962 infrom the ~~current~~outstanding ~~year~~convertible notes and ~~having~~loan balances, an increase in gain on derivative liabilities of $28,334 and a ~~loss~~decrease in gain on settlement of debt of $80115,~~532~~085 from a settlement of accounts payable in the same period of the prior year vs no similar settlement in the current period.

The net loss for the year ended December 31, ~~2024~~2025 was $2,~~001~~669,~~733~~348 as compared to a net loss of $2,~~623~~001,~~267~~733 for the prior year. The ~~decrease~~increase in the net loss ~~was~~is due to the Company having aan ~~decrease~~increase in operating expenses of $~~418~~247,~~967~~902 ~~offset~~and by an increase in other ~~income (~~expense) of $~~202~~419,~~567~~713 during the year ended December 31, ~~2024 to $5~~2025,~~839,~~ as explained above.

1921 Table of Contents

Liquidity and Capital Resources

As of December 31, ~~2024~~2025, the Company had a negative working capital of $13,~~449~~837,~~469~~757. The Company has not yet attained a level of operations, and for the foreseeable future will not achieve commercial operations, which will allow it to meet its current overhead expense obligations. The report of our independent registered public accounting firm on our ~~2024~~2025 and ~~2023~~2024 financial statements includes an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern. The Company generated no revenue during the years ended December 31, ~~2024~~2025 and ~~2023~~2024 due to focusing its capital and resources towards seeking a Class III PMA for its CelluSTAT hemostatic technology. There can be no assurance that adequate financing will continue to be available to the Company and, if available, on terms that are favorable to the Company. Our ability to continue as a going concern is also dependent on many events outside of our direct control, including, among other things, our ability to achieve our business goals and objectives~~, as well as improvement in the economic climate~~.

As discussed in Note 6 of the financial statements, the Company entered into a common stock purchase agreement (“CSPA”) with White Lion, which gives the Company the right, but not the obligation, to require White Lion to purchase up to $10,000,000 of the Company’s common stock, subject to certain limitations and conditions set forth in the CSPA. AsThe ~~of the date of this filing, the~~ Company has received approximately $3.23 million in proceeds from White Lion from the sale of shares under the CSPA which the Company ~~has~~ used to pay for its operations and ~~finalization~~advance of its Class III PMA application. ~~The~~White ~~sale~~Lion’s ofcommitment ~~additional~~under ~~equity~~the orCSPA ~~convertible~~expired ~~debt~~in ~~securities~~October ~~would~~2025. beOn ~~dilutive~~December to16, ~~our~~2025 ~~shareholders.~~we Inentered ~~addition,~~into ~~economic~~an ~~conditions~~Any ~~and~~Markets ~~actions~~Purchase byAgreement ~~policymaking~~(“AMPA”) ~~bodies~~with ~~are~~Alumni ~~contributing~~Capital, toLP, ~~rising~~which ~~interest~~requires ~~rates~~Alumni ~~and~~Capital ~~significant~~to ~~capital~~purchase ~~market~~up ~~volatility~~to $4,000,000 ~~which~~of the Company’s common stock, ~~along~~subject ~~with~~to ~~increases~~certain limitations and conditions set forth in ~~our~~the ~~borrowing~~AMPA. ~~levels,~~The ~~could~~sale ~~increase~~of ~~our~~additional ~~future~~equity ~~borrowing~~or ~~costs~~convertible debt securities would be dilutive to our shareholders.

Cash Flows

The Company’s cash on hand as of December 31, ~~2024~~2025 and ~~2023~~2024 was $~~168~~65,~~883~~249 and $95168,~~420~~883, respectively.

The following table summarizes selected items from our statements of cash flows for the years ended December 31, ~~2024~~2025 and ~~2023~~2024:

	2024			2023
	2025			2024
Net cash used in operating activities	$	(1,~~194~~186,~~716~~942	)	$	(21,~~200~~194,~~645~~716	)
Net cash used in investing activities		-			~~(2,850~~-	)
Net cash provided by financing activities		1,~~268~~083,~~179~~308			21,~~285~~268,~~538~~179
Net increase (decrease) in cash and cash equivalents	$	73(103,~~463~~634	)	$	8273,~~043~~463

Net Cash Provided by (Used in) Operating Activities

Net cash used in operating activities for the year ended December 31, 2025 was $1,186,942. The Company had a net loss of $2,669,348, amortization of right-of-use asset of $810, gain on derivative liabilities of $28,334, and an increase in prepaid and other current assets of $17,343 offset by stock for services and compensation of $1,120,125, amortization of debt discount $1,649, amortization expense of $4,050, an increase in accounts payable and accrued expenses of $224,878, an increase in accrued liabilities - related party of $86,924 and an increase in accrued compensation of $91,267.

Net cash used in operating activities for the year ended December 31, 2024 was $1,194,716. The Company had a net loss of $2,001,733 and a gain on settlement of debt of $115,085 offset by amortization expense of $4,050, stock for services and compensation of $375,000, write-off of inventory of $33,598, amortization of right-of-use asset of $586, a decrease in prepaid and other current assets of $4, an increase in accrued liabilities - related party of $76,924, an increase in accrued compensation of $355,750 and an increase in accounts payable and accrued expenses of $76,190.

Net cash used in operating activities for the year ended December 31, 2023 was $2,200,645. The Company had net loss of $2,623,267 offset by amortization expense of $4,050, amortization of right-of-use asset of $807, amortization of debt discount of $32,992, stock issued for litigation settlement of $462,500, a loss on debt settlement of $80,532, a decrease in inventory of $1,132, a decrease in prepaid and other current assets of $128 and an increase in accrued liabilities - related party of $53,569 and an increase in accrued compensation of $246,577. The Company also had a decrease in accounts payable and accrued expenses of $159,665 and a decrease in accrued litigation settlement of $300,000.

Net Cash Provided by (Used in) Investing Activities

The Company did not have any investing activities during the year ended December 31, 2025.

The Company did not have any investing activities during the year ended December 31, 2024.

~~The~~22 ~~Company~~Table ~~paid~~of ~~$2,850 related to a security deposit during the year ended December 31, 2023.~~Contents

20 Table of Contents

Net Cash Provided by (Used in) Financing Activities

Net cash provided by financing activities for the year ended December 31, ~~2024~~2025 was $1,~~268~~083,~~179~~308. This was due to the result of the Company receiving ~~net~~ proceeds of $~~863~~770,~~579~~000 from ~~the~~convertible ~~sale~~notes, ofreceiving ~~common~~proceeds ~~stock~~of ~~offset~~$250,000 byfrom ~~making~~notes ~~payments~~payable of– ~~$11~~related party,~~400,~~ receiving proceeds of $6665,~~000~~708 from the sale of ~~units,~~common stock offset by making payments of $~~200~~2,~~000~~400, inreceiving ~~proceeds~~advances from arelated ~~convertible~~party ~~note~~of ~~payable, and~~ $~~150~~145,000 inoffset ~~proceeds~~by repayment of advances from arelated ~~promissory~~party ~~note~~of ~~payable~~$145,000.

Net cash provided by financing activities for the year ended December 31, ~~2023~~2024 was $21,~~285~~268,~~538~~179. This was due to the result of the Company receiving ~~net~~ proceeds of $2863,~~326,674~~579 from the sale of common stock offset by making payments of ~~offering~~$11,400, ~~costs~~proceeds of $1766,~~400,~~000 ~~repayments~~from the sale of units, $19200,~~136~~000 onin proceeds from a ~~loan~~convertible note payable, and ~~repayments of~~ $4150,000 onin aproceeds ~~loan~~from ~~payable~~a –promissory ~~related~~note ~~party~~payable.

Off-Balance Sheet Arrangements

As of December 31, ~~2024~~2025 and ~~2023~~2024, we had no off-balance sheet arrangements.

Related Parties

Information concerning related party transactions is included in the financial statements and related notes, appearing elsewhere in this Annual Report on Form 10-K.

Critical Accounting Estimates

The preparation of financial statements in conformity with generally accepted accounting principles of the United States (“GAAP”) requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses in the financial statements and accompanying notes. Critical accounting estimates are those estimates made in accordance with GAAP that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on the financial condition or results of operations of the Company. Based on this definition, we have the critical accounting estimates identified below. We also have other key accounting policies, which involve the use of estimates, judgments, and assumptions that are significant to understanding our results which are found in Note 2 – Significant Accounting Policies of the accompanying financial statements. Although we believe that our estimates, assumptions, and judgments are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments, or conditions.

Stock-Based Compensation

The Company accounts for stock-based compensation under the provisions of ASC 718, Compensation-Stock Compensation. Stock-based compensation expense for employees and non-employees is measured at the grant date fair value. Stock-based compensation for all stock-based awards to employees and directors is recognized as an expense over the requisite service period, which is generally the vesting period.

Warrants

The Company accounts for common stock warrants in accordance with applicable accounting guidance provided in ASC 480 Distinguishing Liabilities from Equity and ASC 815 Derivatives and Hedging, as either derivative liabilities or as equity instruments depending on the specific terms of the warrant agreement. The warrants classified within equity are indexed to the Company’s common stock, provide for settlement in a fixed number of registered or unregistered shares for a fixed exercise price, and are freestanding equity instruments. Accordingly, they meet the criteria for equity classification under ASC 815-40 and are not subject to remeasurement in future periods. For warrants classified as equity instruments the Company applies the Black Scholes model and expenses the fair value as financing costs. For warrants classified as derivative financial instruments, the Company applies the Black Scholes model to value the warrants.

Recent Accounting Pronouncements

See Note 2, “Significant Accounting Policies”.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Smaller reporting companies are not required to provide the information required by this Item.

2123 Table of Contents

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The financial statements required by Item 8 can be found beginning on Page F-2 of this report.

INDEX TO FINANCIAL STATEMENTS AND SUPPLEMENTAL DATA

		Page
Report of Independent Registered Public Accounting Firms (Firm ID 6258)		F-2
Financial Statements of United Health Products, Inc.
Balance Sheets as of December 31, 2024 and 2023		F-3
Balance Sheets as of December 31, 2025 and 2024		F-3
Statements of Operations for the years ended December 31, 2024 and 2023		F-4
Statements of Operations for the years ended December 31, 2025 and 2024		F-4
Statements of Stockholders’ Deficiency for the years ended December 31, 2024 and 2023		F-5
Statements of Stockholders’ Deficiency for the years ended December 31, 2025 and 2024		F-5
Statements of Cash Flows for the years ended December 31, 2024 and 2023		F-6
Statements of Cash Flows for the years ended December 31, 2025 and 2024		F-6
Notes to Financial Statements		F-7

F-1

Table of Contents

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders

United Health Products, Inc.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of United Health Products, Inc. as of December 31, ~~2024~~2025 and ~~2023~~2024, and the related statements of operations, stockholders’ deficiency, and cash flows for each of the years ~~then~~in the period ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of ~~Untied~~United Health Products, Inc. as of December 31, ~~2024~~2025 and ~~2023~~2024, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Going Concern

The accompanying financial statements have been prepared assuming that the entity will continue as a going concern. As discussed in Note 2 to the financial statements, the entity has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the entity’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to United Health Products, Inc. in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. United Health Products, Inc. is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

~~Critical~~The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. ~~We determined that there are no critical audit matters.~~

The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Sufficient Authorized Shares

In determining if the Company has sufficient authorized and unissued shares of common stock to issue for its share-based contracts, there was significant analysis completed by the auditor, including a detailed analysis and interpretation of accounting literature.

In order to perform this analysis, we reviewed management’s analysis and performed a significant amount of research to gain comfort in the conclusions reached (see the “Per Share Information” section of Note 2).

Complex Debt Transactions

During the year under audit, the Company entered into an Any Market Purchase Agreement (“AMPA”). In consideration for the investor’s execution and performance under the AMPA, the Company issued a Purchase Warrant (“the Warrant”) to purchase up to 3,484,321 shares of the Company’s common stock (see Note 6). The terms of the Warrant require the Warrant to be accounted for as a liability. Calculations and accounting for the AMPA and Warrant require management’s judgments related to initial and subsequent recognition of the AMPA and related Warrant, use of a valuation model, and determination of appropriate inputs used in the selected valuation model.

In order to audit the accounting for the AMPA and purchase warrant, we evaluated management’s analysis of the transaction, performed a significant amount of research and analysis, confirmed key terms of the agreements directly with the investor, and performed an independent assessment of the appropriate valuation model for derivatives, performing independent calculations based on the model and comparing the Company’s results to a reasonable range as determined during the audit.

/s/ Mac Accounting Group & CPAs, LLP

We have served as United Health Products, Inc.'’s auditor since 2019.

Midvale, Utah

~~March 28~~April 15, ~~2025~~2026

F-2

Table of Contents

UNITED HEALTH PRODUCTS, INC.

~~Balance~~BALANCE ~~Sheets~~SHEETS

	December 31,			December 31,
	2024			2023
	2025			2024
ASSETS
Current Assets
Cash and Cash Equivalents	$	168,883		$	95,420
Cash and cash equivalents	$	65,249		$	168,883
Inventory		-			33,598
Prepaid and other current assets		40,143			22,800
Prepaid and other current assets		22,800			22,804
Total current assets		105,392			191,683
Total current assets		191,683			151,822
Deferred offering costs		169,582			-
Deferred offering costs		-			21,051
Operating lease right-of-use asset		14,574			47,096
Operating lease right-of-use asset		47,096			76,520
Security deposit		2,850			2,850
Patents, net		2824,~~350~~300			3228,~~400~~350
TOTAL ASSETS	$	~~269~~316,~~979~~698		$	~~284~~269,~~643~~979
Current Liabilities
Accounts payable and accrued expenses	$	~~830~~1,~~672~~052,255		$	~~869~~830,~~567~~672
Accrued liabilities - related parties		~~168~~255,~~649~~573			91168,~~725~~649
Accrued compensation		~~608~~699,~~500~~767			~~252~~608,~~750~~500
Operating lease liability - current		3315,~~331~~157			2833,~~838~~331
Convertible notes payable, net of debt discount		-			207,500
Convertible notes payable – related party, net of debt discount		-			500,000
Total current liabilities		1,641,152			1,950,380
Convertible notes payable, net of debt discount		557,500			-
Convertible notes payable – related party, net of debt discount		500,000			-
Operating lease liability – long-term		15,158			48,489
Convertible notes payable, net of debt discount		1,279,149			-
TOTAL LIABILITIES		2,713,810			1,998,869
Derivative liabilities		141,248			-
Total current liabilities		3,943,149			1,641,152
Convertible notes payable, net of debt discount		-			557,500
Notes payable – related party		250,000			-
Convertible notes payable – related party, net of debt discount		-			500,000
Operating lease liability – long-term		-			15,158
TOTAL LIABILITIES		4,193,149			2,713,810
Commitments and Contingencies		-			-
Stockholders’ Deficit
Series A Convertible Preferred Stock - $0.001 par value, 1,000,000 shares Authorized and 0 shares issued and outstanding		-			-
Common Stock - $0.001 par value, 300,000,000 shares Authorized, 252,408,222 and 244,783,222 shares issued and outstanding at December 31, 2024 and December 31, 2023		252,408			244,783
Common Stock - $0.001 par value, 300,000,000 shares Authorized, 258,690,253 and 252,408,222 shares issued and outstanding at December 31, 2025 and December 31, 2024		258,690			252,408
Additional Paid-In Capital		7677,~~004~~235,~~704~~150			7476,~~740~~004,~~201~~704
Accumulated Deficit		(7881,~~700~~370,~~943~~291	)		(7678,~~699~~700,~~210~~943	)
Total Stockholders' Deficit		(2,443,831	)		(1,714,226	)
Total Stockholders’ Deficit		(3,876,451	)		(2,443,831	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	~~269~~316,~~979~~698		$	~~284~~269,~~643~~979

See notes to financial statements.

F-3

Table of Contents

UNITED HEALTH PRODUCTS, INC

~~Statements~~STATEMENTS ofOF ~~Operations~~OPERATIONS

	2024			2023
	2025			2024
Revenues	$	-		$	-
Operating Costs and Expenses
Selling, general and administrative expenses		1,~~651~~985,~~636~~607			1,~~827~~651,~~729~~636
Research and development expenses		~~355~~269,~~936~~867			~~598~~355,~~810~~936
Total Operating Expenses		2,~~007~~255,~~572~~474			2,~~426~~007,~~539~~572
Loss from Operations		(2,~~007~~255,~~572~~474	)		(2,~~426~~007,~~539~~572	)
Other income (expenses)
Interest expense		(32113,~~322~~284	)		(4032,~~512~~322	)
Interest expense – related party		(7686,924	)		(7576,~~684~~924	)
Gain (loss) on settlement of debt		115,085			(80,532	)
Gain (loss) on derivative liabilities		28,334			-
Total Other Income (Expense)		5,839			(196,728	)
Fraud loss		(242,000	)		-
Gain (loss) on settlement of debt		-			115,085
Total Other Income (Expense)		(413,874	)		5,839
Income tax expense		-			-
Net Loss	$	(2,~~001~~669,~~733~~348	)	$	(2,~~623~~001,~~267~~733	)
Net Loss per common share:
Basic and diluted	$	(0.01	)	$	(0.01	)
Weighted average number of shares outstanding		~~248~~256,~~173~~981,~~249~~335			~~239~~248,~~080~~173,~~282~~249

See notes to financial statements.

F-4

Table of Contents

UNITED HEALTH PRODUCTS, INC

~~Statement~~STATEMENT ofOF ~~Stockholders~~STOCKHOLDERS’ ~~Deficiency~~DEFICIENCY

For the Years Ended December 31, ~~2024~~2025 and ~~2023~~2024

					Additional
	Common Stock				Paid-in			~~Subscription~~Accumulated			~~Accumulated~~
	Shares		Amount		Capital			~~Receivable~~Deficit			~~Deficit~~Total			~~Total~~
Balance at December 31, 2022		230,871,034	$	230,871	$	71,830,695		$	(50,550	)	$	(74,075,943	)	$	(2,064,927	)
Balance at December 31, 2023		244,783,222	$	244,783	$	74,740,201		$	(76,699,210	)	$	(1,714,226	)
Sale of common stock, net of $17,400 of offering costs		10,145,000		10,145		2,247,979			50,550			-			2,308,674
Sale of common stock, net of $11,400 of offering costs		5,300,000		5,300		846,879			-			852,179
Common stock issued to settle accrued liabilities – related party		1,204,688		1,204		269,827			-			-			271,031
Sale of units for cash		825,000		825		65,175			-			66,000
Common stock issued to settle accrued liabilities		712,500		713		153,038			-			-			153,751
Vesting of restricted stock units		1,500,000		1,500		373,500			-			375,000
Common stock issued for litigation settlement		1,850,000		1,850		460,650			-			-			462,500
Amortization of deferred offering costs		-		-		(21,051	)		-			(21,051	)
Amortization of deferred offering costs		-		-		(221,988	)		-			-			(221,988	)
Net Loss		-		-		-			(2,001,733	)		(2,001,733	)
Net Loss		-		-		-			-			(2,623,267	)		(2,623,267	)
Balance at December 31, 2024		252,408,222		252,408		76,004,704			(78,700,943	)		(2,443,831	)
Balance at December 31, 2023		244,783,222		244,783		74,740,201			-			(76,699,210	)		(1,714,226	)
Sale of common stock, net of $2,400 of offering costs		800,000		800		62,508			-			63,308
Sale of common stock, net of $11,400 of offering costs		5,300,000		5,300		846,879			-			-			852,179
Common stock issued for conversion of note payable		757,031		757		52,538			-			53,295
Sale of units for cash		825,000		825		65,175			-			-			66,000
Vesting of restricted stock units		4,725,000		4,725		1,115,400			-			1,120,125
Vesting of restricted stock units		1,500,000		1,500		373,500			-			-			375,000
Net Loss		-		-		-			(2,669,348	)		(2,669,348	)
Amortization of deferred offering costs		-		-		(21,051	)		-			-			(21,051	)
Balance at December 31, 2025		258,690,253	$	258,690	$	77,235,150		$	(81,370,291	)	$	(3,876,451	)
Net Loss		-		-		-			-			(2,001,733	)		(2,001,733	)
Balance at December 31, 2024		252,408,222	$	252,408	$	76,004,704		$	-		$	(78,700,943	)	$	(2,443,831	)

See notes to financial statements.

F-5

Table of Contents

UNITED HEALTH PRODUCTS, INC

~~Statements~~STATEMENTS ofOF ~~Cash~~CASH ~~Flows~~FLOWS

	2024			2023
	2025			2024
Cash Flows from Operating Activities:
Net Loss	$	(2,~~001~~669,~~733~~348	)	$	(2,~~623~~001,~~267~~733	)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Stock for services and compensation		~~375~~1,~~000~~120,125			-375,000
Write-off of inventory		~~33,598~~-			-33,598
(Gain) loss on settlement of debt		~~(115,085~~-	)		80(115,~~532~~085	)
Amortization of right-of-use asset		~~586~~(810	)		~~807~~586
Stock issued for litigation settlement		-			462,500
(Gain) loss on derivative liabilities		(28,334	)		-
Amortization of debt discount		-1,649			~~32,992~~-
Amortization expense		4,050			4,050
Changes in assets and liabilities:
Inventory		-			~~1,132~~-
Prepaid and other current assets		4(17,343	)		~~128~~4
Accounts payable and accrued expenses		76224,~~190~~878			~~(159~~76,~~665~~190	)
Accrued compensation		~~355~~91,~~750~~267			~~246~~355,~~577~~750
Accrued litigation settlement		-			(300,000	)
Accrued liabilities – related party		86,924			76,924
Accrued liabilities – related party		76,924			53,569
Net Cash Used For Operating Activities		(1,186,942	)		(1,194,716	)
Net Cash Used In Operating Activities		(1,194,716	)		(2,200,645	)
Cash Flows from Investing Activities:
Security deposit		-			(2,850	)
Net Cash Used For Investing Activities		-			-
Net Cash Used In Investing Activities		-			(2,850	)
Cash Flows from Financing Activities:
Repayment on loan payable - related parties		-			(4,000	)
Advance from related party		145,000			-
Repayments on loan payable		-			(19,136	)
Repayments of advance from related party		(145,000	)		-
Proceeds from promissory note payable		150,000			-
Proceeds from note payable – related party		250,000			-
Proceeds from convertible notes payable		200,000			-
Proceeds from promissory note payable		-			150,000
Payment of offering costs		(11,400	)		(17,400	)
Proceeds from convertible notes payable		770,000			200,000
Proceeds from sale of common stock		863,579			2,326,074
Payment of offering costs		(2,400	)		(11,400	)
Proceeds from sale of units		66,000			-
Proceeds from sale of common stock		65,708			863,579
Net Cash Provided By Financing Activities		1,268,179			2,285,538
Proceeds from sale of units		-			66,000
Increase (decrease) in Cash and Cash Equivalents		73,463			82,043
Net Cash Provided By Financing Activities		1,083,308			1,268,179
Cash and Cash Equivalents - Beginning of period		95,420			13,377
Increase (decrease) in Cash and Cash Equivalents		(103,634	)		73,463
CASH AND CASH EQUIVALENTS - END OF PERIOD	$	168,883		$	95,420
Cash and Cash Equivalents - Beginning of period		168,883			95,420
CASH AND CASH EQUIVALENTS - END OF PERIOD	$	65,249		$	168,883
Supplemental cash flow information:
Cash paid for interest	$	-		$	~~703~~-
Cash paid for income taxes	$	-		$	-
Schedule of Non-Cash Financing Activities:
Common stock issued to settle accrued liabilities – related party	$	-		$	218,250
Common stock issued for conversion of convertible note and accrued interest	$	53,295		$	-
Common stock issued to settle accounts payable and accrued liabilities	$	-		$	126,000
Amortization of deferred offering costs	$	-		$	21,051
Accounts payable and accrued expenses paid with promissory note payable	$	-		$	10,000
Transfer of promissory note payable to convertible note	$	-		$	150,000
Initial recognition of operating lease right-of-use asset and operating lease liability	$	-		$	92,425
Deferred offering asset and derivative liability associated with warrants	$	169,582		$	-
Amortization of deferred offering costs	$	21,051		$	221,988
OID on convertible note	$	39,267		$	-
Transfer of promissory note payable to convertible note	$	150,000		$	-

See notes to financial statements.

F-6

Table of Contents

UNITED HEALTH PRODUCTS, INC.

NOTES TO FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, ~~2024~~2025 AND ~~2023~~2024

Note 1. Description of the Business

The Company develops, manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. Our gauze product, CelluSTAT® (formerly branded as HemoStyp), is derived from cotton and designed to absorb exudate/drainage from superficial wounds and help control bleeding. We are in the process of seeking regulatory approval to sell our hemostatic gauze product line into the U.S. Class III human surgical markets.

Note 2. Significant Accounting Policies

Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring net losses, negative working capital and operations have not provided cash flows. Additionally, the Company does not currently have sufficient revenue producing operations to cover its operating expenses and meet its current obligations. In view of these factors, there is substantial doubt about the Company'’s ability to continue as a going concern. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital and other business requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Basis of Presentation

The Company prepares its financial statements on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ.

Cash and Cash Equivalents

The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents.

F-7

Table of Contents

Fair Value Measurements

Accounting principles generally accepted in the United States define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Additionally, the inputs used to measure fair value are prioritized based on a three-level hierarchy. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

Level 1 — Quoted prices in active markets for identical assets or liabilities.

Level 2 — Observable inputs other than quoted prices included in Level 1. We value assets and liabilities included in this level using dealer and broker quotations, bid prices, quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable market data.

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

~~Fair~~If ~~value~~the ~~estimates~~inputs ~~discussed~~used ~~herein~~to ~~are~~measure ~~based~~the ~~upon~~financial ~~certain~~assets ~~market assumptions~~ and ~~pertinent~~liabilities ~~information~~fall ~~available~~within tomore ~~management~~than asone oflevel ~~December~~described 31above, ~~2024~~the ~~and~~categorization ~~2023.~~is ~~The~~based ~~respective~~on ~~carrying~~the ~~value~~lowest level of ~~certain~~input ~~on-balance-sheet~~that ~~financial~~is ~~instruments~~significant ~~approximated~~to ~~their~~the fair ~~values~~value ~~due~~measurement toof the ~~short-term nature of these instruments~~instrument.

The following table provides a summary of the fair value of the Company’s derivative liabilities as of December 31, 2025 and 2024:

	Fair value measurements on a recurring basis
	Level 1		Level 2		Level 3
As of December 31, 2025:
Liabilities
Derivative liabilities	$	-	$	-	$	141,248

As of December 31, 2024:
Liabilities
Derivative liabilities	$	-	$	-	$	-

Warrants: The Company accounts for common stock warrants in accordance with applicable accounting guidance provided in ASC 480 Distinguishing Liabilities from Equity and ASC 815 Derivatives and Hedging, as either derivative liabilities or as equity instruments depending on the specific terms of the warrant agreement. The warrants classified within equity are indexed to the Company’s common stock, provide for settlement in a fixed number of registered or unregistered shares for a fixed exercise price, and are freestanding equity instruments. Accordingly, they meet the criteria for equity classification under ASC 815-40 and are not subject to remeasurement in future periods. For warrants classified as equity instruments, the Company applies the Black Scholes model and expenses the fair value as financing costs. For warrants classified as derivative financial instruments, the Company applies the Black Scholes model to value the warrants.

Income Taxes

The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company’s assets and liabilities which is commonly known as the asset and liability method. In assessing the ability to realize deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company evaluates its tax positions taken or expected to be taken in the course of preparing the Company’s tax returns to determine whether the tax positions are ‘‘“more-likely-than-not’’” of being sustained by the applicable tax authority. Tax positions not deemed to meet the “more-likely-than-not” threshold are recorded as an expense in the applicable year. The Company does not have a liability for any unrecognized tax benefits. Management’s evaluation of uncertain tax positions may be subject to review and adjustment at a later date based upon factors including, but not limited to, an on-going analysis of tax laws, regulations and interpretations thereof, with due consideration given to the fact that tax periods are open to examination by tax authorities.

As of December 31, ~~2024~~2025 and ~~2023~~2024, the Company has approximately $~~25.2~~27 million and $2325.82 million of net operating loss carry-forwards, respectively, available to affect future taxable income and has established a valuation allowance equal to the tax benefit of the net operating loss carry forwards and temporary differences as realization of the asset is not assured.

F-8

Table of Contents

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sale of its CelluSTAT product by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

The Company receives orders for its CelluSTAT products directly from its customers. Revenues are recognized based on the agreed upon sales or transaction price with the customer when control of the promised goods are transferred to the customer. The transfer of goods to the customer and satisfaction of the Company’s performance obligation will occur either at the time when products are shipped or when the products arrive and are received by the customer depending on the shipping terms. No discounts are offered by the Company as part of payment terms. The Company does not provide an estimate for returns as there is no anticipation for any returns in the normal course of business.

Trade Accounts Receivable and Concentration Risk

The Company records accounts receivable at the invoiced amount and does not charge interest. The Company reviews the accounts receivable by amounts due from customers which are past due to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, the Company makes judgments about the creditworthiness of significant customers based on ongoing credit evaluations. The Company will also maintain a sales allowance to reserve for potential credits issued to customers. The Company will determine the amount of the reserve based on historical credits issued.

There was no provision for doubtful accounts recorded at December 31, ~~2024~~2025 and ~~2023~~2024. The Company recorded $0 in bad debt expense for the years ended December 31, ~~2024~~2025 and ~~2023~~2024.

Inventory

Inventory is valued at the lower of cost or net realizable value using the first-in, first-out (FIFO) method. Inventory on the balance sheet consists of raw materials purchased by the Company and finished goods.

	December 31,2024		December 31,2023
	December 31,2025		December 31,2024
Raw materials	$	-	$	-
Finished goods		-		~~33,598~~-
	$	-	$	33,598

During the ~~year~~years ended December 31, ~~2023~~2025 and 2024, the Company ~~used~~determined that $10 and $33,~~132~~598 of inventory needed ~~for~~to ~~its~~be ~~PMA~~impaired ~~submission~~ and ~~recorded~~written-off, ~~it to research and development~~respectively.

During the years ended December 31, 2024 and 2023, the Company determined that $33,598 and $0 of inventory needed to be impaired and written-off, respectively.

F-9

Table of Contents

Patents

Patents are stated on the balance sheet at cost. Costs, such as filing fees with patent granting agencies and legal fees directly relating to those filings, incurred to file patent applications were capitalized when the Company believed that there was a high likelihood that the patent would be issued and there would be future economic benefit associated with the patent. These costs were amortized from the date of the patent application on a straight-line basis over the estimated useful life of 10 years. All costs associated with any abandoned patent applications are expensed.

Accumulated amortization as of December 31, ~~2024~~2025 and December 31, ~~2023~~2024 was $1216,~~150~~200 and $812,~~100~~150, respectively. Amortization expense for the years ended December 31, ~~2024~~2025 and ~~2023~~2024 was $4,050 and $4,050, respectively.

Future Amortization Expense

Year	Amount
2025	$	4,050
2026	$	4,050
2026		4,050
2027		4,050
2028		4,050
Thereafter		12,150
2029		4,050
	$	28,350
Thereafter		8,100
	$	24,300

Impairment of Long-lived Assets

The Company applies the provisions of ASC 360, Property, Plant and Equipment, where applicable to all long-lived assets. ASC 360 addresses accounting and reporting for impairment and disposal of long-lived assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with ASC 360. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.

When equipment is sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is included in the results of operations. During the years ended December 31, ~~2024~~2025 and ~~2023~~2024 the Company determined no impairment was required.

Deferred Offering Costs

Deferred offering costs represent specific incremental costs directly attributable to the offering of securities. The deferred offering costs are recorded as an offset to additional paid-in capital or derivative liabilities and charged against ~~the~~ proceeds received based on expected proceeds. The Company had $169,582 and $0 deferred offering costs as of December 31, 2025 and 2024, respectively.

Advertising and Marketing Costs

Advertising and marketing costs are expensed as incurred. The Company incurred $~~111~~123,~~824~~024 and $111,~~104~~824 in advertising and marketing costs during the years ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively.

Shipping and Handling Costs

The Company includes shipping and handling cost as part of cost of goods sold.

Research and Development

The Company charges research and development costs to ~~expense~~expenses when incurred. The Company incurred $~~355~~269,~~936~~867 and $~~598~~355,~~810~~936 in research and development expenses during the years ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively.

Stock-Based Compensation

F-10

Table of Contents

Per Share Information

Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted earnings per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. The dilutive effect of potential common shares is not reflected in diluted earnings per share because the Company incurred a net loss for the years ended December 31, ~~2024~~2025 and ~~2023~~2024 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive.

The total potential common shares asincluded ~~of December 31~~40, ~~2024 include 46~~315,~~165,~~000 of restricted stock units (RSU), 910,~~197~~732,~~376~~577 shares for convertible notes payable – related parties, 10accounted for as stock settled debt,~~678~~ 23,~~412~~613,654 shares for convertible notes payable, accounted for as stock settled debt, and ~~412~~3,~~500~~896,821 shares for warrants. The total potential common shares as of December 31, ~~2023~~2024 include 4746,~~665~~165,000 of restricted stock units, 39,~~747~~197,~~463~~376 shares for convertible notes payable – related parties, ~~and~~accounted 1for as stock settled debt,~~483~~ 10,~~530~~678,412 shares for convertible notes payable, accounted for as stock settled debt, and 412,500 shares for warrants.

The Company has elected to sequence its freestanding equity instruments based on inception date in reverse chronological order to determine the sufficiency of authorized shares available for issuance. As of December 31, 2025, the Company determined that there are sufficient authorized shares for issuance as our restricted stock units are not likely to vest prior to December 31, 2026, due to the various performance conditions within the restricted stock unit agreements.

Segment Reporting

United Health Products, Inc. operates as a single operating segment, focusing on the development and commercialization of medical devices, particularly its patented hemostatic gauze, CelluSTAT™.

The accounting policies of the operating segment are the same as those described in the summary of significant accounting policies. The Company’s chief operating decision maker (“CODM”) is the Chief Executive Officer. The CODM assesses performance for the segment and decides how to allocate resources based on net income (loss) that is reported on the income statement. The measure of segment assets is reported on the balance sheet as total assets.

As the Company did not generate revenues in ~~2024~~the current period, the CODM assessed Company performance through the achievement of target identification goals. In addition to the Company'’s Statement of Operations, the CODM regularly ~~works~~develops ~~with~~and ~~the Principal Financial Officer to develop~~ maintains budgeted and forecasted expense information which is used to determine the Company'’s liquidity needs and cash allocation.

Leases

The Company follows the provisions of ASC 842, and records right-of-use (“ROU”) assets and lease obligations for its operating leases, which are initially recognized based on the discounted future lease payments over the term of the lease. If the rate implicit in the Company'’s leases is not readily determinable, the Company'’s applicable incremental borrowing rate is used in calculating the present value of the sum of the lease payments.

The lease term is defined as the non-cancelable period of the lease plus any options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company has elected not to recognize ROU asset and lease obligations for its short-term leases, which are defined as leases with an initial term of 12 months or less.

Reclassifications

Certain prior period amounts in the accompanying audited financial statements have been reclassified to conform to the current period’s presentation. These reclassifications had no effect on the results of operations or financial position for any period presented.

New and Recently Adopted Accounting Pronouncements

In ~~November~~December 2023, the FASB issued ASU 2023-0709, ~~Segment~~Income ~~Reporting~~Taxes (Topic ~~280~~740): Improvements to ~~Reportable~~Income ~~Segment~~Tax Disclosures, which ~~updates~~expands ~~reportable~~the ~~segment disclosure~~ requirements ~~primarily~~for ~~through~~income ~~enhanced~~tax disclosures ~~about~~in ~~significant~~order ~~segment~~to ~~expenses~~provide greater transparency. The amendments are effective for fiscal years beginning after December 15, ~~2023, and for interim periods within fiscal years beginning after December 15,~~ 2024. The Company adopted the ASU for the fiscal year ended December 31, ~~2024~~2025. The amendments only impact disclosures and are not expected to have an impact on the Company'’s financial condition and results of operations.

In ~~December~~November ~~2023~~2024, the FASB issued ASU ~~2023~~2024-0903, Income ~~Taxes~~Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (~~Topic~~Subtopic ~~740~~220-40): ~~Improvements~~Disaggregation toof Income ~~Tax~~Statement ~~Disclosures~~Expenses, which ~~expands~~requires ~~the~~incremental ~~requirements~~disclosures ~~for~~about ~~income~~specific ~~tax~~expense ~~disclosures~~categories, inincluding ~~order~~but not limited to, ~~provide~~purchases ~~greater~~of ~~transparency~~inventory, employee compensation, depreciation, amortization and selling expenses. The amendments are effective for fiscal years beginning after December 15, ~~2024~~2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. ~~The~~and the amendments ~~should~~may be applied either prospectively, ~~although~~or ~~optional retrospective application is permitted~~retrospectively. The Company is currently evaluating this ASU to determine its impact on the Company'’s disclosures. The amendments only impact disclosures and are not expected to have an impact on the Company'’s financial condition and results of operations.

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires incremental disclosures about specific expense categories, including but not limited to, purchases of inventory, employee compensation, depreciation, amortization and selling expenses. The amendments are effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted and the amendments may be applied either prospectively or retrospectively. The Company is currently evaluating this ASU to determine its impact on the Company's disclosures. The amendments only impact disclosures and are not expected to have an impact on the Company's financial condition and results of operations.

The Company considers all new pronouncements and management has determined that there have been no recently adopted or issued accounting standards that had or will have a material impact on its financial statements.

F-11

Table of Contents

Note 3. Related Party Transactions

Convertible notes payable - related parties

As of December 31, ~~2024~~2025 and ~~2023~~2024, convertible notes payable – related parties (net of debt discount) totaled $500,000 and $500,000, respectively.

During the year ended December 31, 2022, Brian Thom, the Company’s Chief Executive Officer, converted $372,000 of a loan payable balance to a convertible note payable. The unpaid accrued interest on the loan payable was transferred to the convertible note payable. The note had an interest rate of 10%, an original issue discount (“OID”) of 7% and had a maturity date of December 31, 2023. ~~The~~At the option of the holder, the note is convertible into common stock of the Company at $0.35 per share. In the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.35 per share, the conversion price shall be reduced to equal such lower issue price per share. The Company recorded $28,000 of a debt discount related to the OID. As of December 31, ~~2024~~2025 and December 31, ~~2023~~2024, the remaining unamortized debt discount was $0 and $0, respectively. Accrued interest associated with the note was $~~139~~209,~~334~~447 and $77139,~~287~~334 as of December 31, ~~2024~~2025 and ~~2023~~2024, respectively.

During the year ended December 31, 2022, Robert Denser, a Director of the Company, loaned the Company $93,000 through a convertible note. The note had an interest rate of 10%, an OID of 7% and had a maturity date of December 31, 2023. ~~The~~At the option of the holder, the note is convertible into common stock of the Company at $0.35 per share. In the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.35 per share, the conversion price shall be reduced to equal such lower issue price per share. The Company recorded $7,000 of a debt discount related to the OID. As of December 31, ~~2024~~2025 and December 31, ~~2023~~2024, the remaining unamortized debt discount was $0 and $0, respectively. Accrued interest associated with the note was $2946,~~315~~126 and $1429,~~438~~315 as of December 31, ~~2024~~2025 and ~~2023~~2024, respectively.

On December 15, 2023, the Company entered into amendments on the above convertible notes, which extended the maturity date to December 31, 2024 and increased the interest rate from 10% to 13%, effective January 1, 2024. On December 20, 2024, the Company entered into amendments on the above convertible notes, which extended the maturity date to December 31, 2026.

Interest expense – related party on the above convertible notes payable was $7686,924 (including $0 of debt discount amortization related to the OID) and $7576,~~462~~924 (including $~~21,669~~0 of debt discount amortization) during the year ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively. Accrued interest – related party due to these convertible notes was $~~168~~255,~~649~~573 and $91168,~~725~~649, as of December 31, ~~2024~~2025 and ~~2023~~2024, respectively.

~~The~~Note ~~following~~payable ~~represents the future aggregate maturities as of December 31, 2024 of the Company’s Convertible Notes Payable~~ – ~~Related~~related ~~Parties:~~parties

	Amount
2025	$	-
2026		500,000
Total	$	500,000

During the year ended December 31, 2025, the Company’s Chief Executive Officer (CEO) advanced the Company $250,000 to secure a private investment, which is unsecured and non-interest bearing. This note payable was to be repaid from the proceeds of a private investment. In the event that the private investment or similar investment is not completed within 120 days of the execution of this note payable, then the CEO may, at his discretion, demand that the Company commit to apply not less than 25% of the net proceeds of any external capital raising activity (including but not limited to equity placements under any Equity Line of Credit then in effect) towards the repayment of the note payable until it is repaid in full. Any unpaid amounts under this note payable shall be due and payable upon the closing of a sale of all, or substantially, all of the assets of the Company. In addition, any amounts under this note payable unpaid on the seventh (7th) anniversary shall be due and payable one hundred twenty (120) days following demand for payment. As of December 31, 2025, the remaining principal balance due was $250,000.

The following represents the future aggregate maturities as of December 31, 2025 of the Company’s Note payable – related party:

	Amount
2026	$	-
2027		-
2028		-
2029		-
2030		-
Thereafter		250,000
Total	$	250,000

Loans payable/advances - related parties

During the year ended December 31, ~~2022~~2025, ~~Kristofer Heaton,~~ the ~~Principal~~Company’s ~~Financial~~Chief Executive Officer, ~~loaned~~advanced the Company $4145,000 to pay for operating expenses., ~~The~~which ~~loan~~was ~~had~~unsecured, an non-interest ~~rate~~bearing ~~of 10%~~ and ~~was~~ due on demand. During the year ended December 31, ~~2023,~~2025 the Company repaid $4145,000 of ~~principal~~the ~~and~~advance resulting in a $~~446~~0 ofadvance balance recorded in accrued ~~interest~~liabilities ~~leaving~~–related aparties ~~balance~~on ofthe $0balance sheet as of December 31, ~~2023~~2025.

Interest expense – related party on the above loan was $0 and $222 during the years ended December 31, 2024 and 2023, respectively. Accrued interest – related party as of December 31, 2024 and 2023 was $0.

Equity transactions

During the year ended December 31, 2023, the Company issued 1,204,688 shares of common stock with a fair value of $271,031 to its officers and management for $218,250 of accrued compensation (see Note 6) which resulted in $52,781 being recorded as a loss on settlement of debt.

F-12

Table of Contents

Note 4. Promissory Note Payable

During the year ended December 31, 2022, the Company entered into a $100,000 promissory note with its legal counsel which accrued interest at 1%, required monthly payments of $9,136 until the balance was paid in full and was secured by 200,000 shares of restricted common stock which would have demand registration rights and the Company would file a registration statement within 45 days of the request.

During the year ended December 31, 2022, the Company paid $90,864 of principal and $500 in interest expense leaving a principal balance of $9,136 and accrued interest of $0 as of December 31, 2022.

During the year ended December 31, 2023, the Company paid the remaining principal balance of $9,136. As of December 31, 2023, the principal balance and accrued interest was $0.

During the year ended December 31, 2023, $10,000 of accounts payable and accrued liabilities were paid on behalf of the Company. The Company entered into a note payable for the $10,000 payment. The note payable had an interest rate of 5% and a maturity date of December 31, 2023. During the year ended December 31, 2023, the Company repaid $10,000 of principal and $256 of accrued interest leaving a balance of $0 as of December 31, 2023.

On August 5, 2024, the Company entered into a $150,000 promissory note with a third-party lender, which was non-interest bearing and had a maturity date of 60 days. On October 28, 2024, the Company entered into an amendment to this promissory note, which extended the maturity date to 120 days. On December 16, 2024, the Company rolled the $150,000 promissory note into a convertible note agreement with this third-party lender (see Note 5). As of December 31, 2024, there was $0 principal balance on the promissory note.

Interest expense on the above loans was $0 and $256 during the years ended December 31, 2024 and 2023, respectively. Accrued interest as of December 31, 2024 and 2023 was $0.

Note 5. Convertible Notes

During the year ended December 31, 2022, the Company issued a $100,000 convertible note and a $107,500 convertible note and received total proceeds of $192,975. The notes had an interest rate of 10%, an OID of 7% and had a maturity date of December 31, 2023. ~~The~~At the option of the holder, the notes are convertible into common stock of the Company at $0.35 per share. In the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.35 per share, the conversion price shall be reduced to equal such lower issue price per share. The Company recorded $14,525 of a debt discount related to the OID. As of December 31, ~~2024~~2025 and December 31, ~~2023~~2024, the remaining unamortized debt discount was $0 and $0, respectively.

On December 15, 2023, the Company entered into amendments on the above convertible notes, which extended the maturity dates to December 31, 2024 and increased the interest rates from 10% to 13%, effective January 1, 2024. On December 20, 2024, the Company entered into amendments to the aforementioned convertible notes, which extended the maturity dates to December 31, 2026.

During the year ended December 31, 2024, the Company issued a $350,000 convertible note and received total proceeds of $200,000. The remaining $150,000 was rolled from a promissory note with this third-party lender (see Note 4). The note has an interest rate of 13% and a maturity date of December 31, 2026. ~~The~~At the option of the holder, the note is convertible into common stock of the Company at $0.05 per share. In the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.05 per share, the conversion price shall be reduced to equal such lower issue price per share.

~~Interest~~On ~~expense~~October on7, 2025, the ~~above~~Company ~~convertible~~entered ~~notes~~into ~~payable~~a ~~was~~ $32100,~~322~~000 ~~(including~~convertible $0promissory ofnote ~~debt~~with ~~discount~~a ~~amortization~~third-party ~~related~~lender, towhich ~~the~~carried ~~OID)~~an interest rate of 13% and ~~$32,875~~had ~~(including~~a ~~$11,323~~maturity date of ~~debt~~60 ~~discount~~days. ~~amortization~~At ~~related~~the tooption of the ~~OID)~~holder, ~~during~~the note is convertible into common stock of the ~~year~~at ~~ended~~a ~~December~~conversion ~~31,~~price ~~2024~~of ~~and~~$0.085 ~~2023,~~per ~~respectively~~share. ~~Accrued~~In ~~interest~~the asevent the Company issues any shares of ~~December~~common ~~31,~~stock ~~2024~~before ~~and~~the ~~December~~maturity ~~31,~~date ~~2023~~at ~~was~~a ~~$59,071~~priced ~~and~~that is lower than $~~26,749,~~0.085 ~~respectively~~per share, ~~and~~ ~~has~~the ~~been~~conversion ~~recorded~~price inshall ~~accrued~~be ~~liabilities~~reduced onto equal such lower issue price per share. The Company entered into subsequent amendments to this promissory note, which extended the ~~balance~~maturity ~~sheet~~date to July 31, 2026.

During the year ended December 31, 2025, the Company issued $420,000 of convertible notes. The ~~following~~notes ~~represents~~have an interest rate of 13% and a maturity of December 31, 2026. At the ~~future~~option ~~aggregate~~of ~~maturities~~the asholder, the notes are convertible into common stock of the Company between $0.12 and $0.085 per share. In the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.12 and $0.085 per share, the conversion price shall be reduced to equal such lower issue price per share. During the year ended December 31, ~~2024~~2025, $50,000 of these convertible notes and $3,295 of accrued interest was converted into shares of the Company’s ~~Convertible~~common ~~Notes~~stock ~~Payable:~~(see Note 6).

	Amount
2025	$	-
2026		557,500
Total	$	557,500

During the year ended December 31, 2025, the Company issued a $289,267 convertible note and received total proceeds of $250,000. The notes had an interest rate of 15%, an OID of 14% and a maturity date of December 31, 2026. The notes are convertible into common stock of the Company at $0.06 per share. In the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.06 per share, the conversion price shall be reduced to equal such lower issue price per share. The Company recorded $39,267 of a debt discount related to the OID. As of December 31, 2025, the remaining unamortized debt discount was $37,618.

Interest expense on the above convertible notes payable was $113,284 (including $1,649 of debt discount amortization related to the OID) and $32,322 (including $0 of debt discount amortization related to the OID) during the year ended December 31, 2025 and 2024, respectively. Accrued interest as of December 31, 2025 and December 31, 2024 was $167,411 and $59,071, respectively, and has been recorded in accounts payable and accrued expenses on the balance sheet.

The Company treats the above convertible notes as stock settled debt in accordance with ASC 480, “Distinguishing Liabilities from Equity” and measures the fair value of the notes at the time of issuance. As the fair value of the notes was not materially different than their face value, no discount was recorded. The conversion features are not considered freestanding equity instruments.

F-13

Table of Contents

Note 6. ~~Issuances~~Common ~~of Securities~~Stock

Share Issuances 2023

During the year ended December 31, 2023, the Company had the following common stock transactions:

· 1,204,688 shares of common stock with a fair value of $271,031 were issued to officers and management of the Company to settle $218,250 of accrued liabilities (see Note 3) resulting in a loss on settlement of debt of $52,781. · 712,500 shares of common stock with a fair value of $153,751 were issued to consultants to settle $126,000 of accrued liabilities resulting in a loss on debt settlement of $27,751. · 10,145,000 shares of common stock were sold for $2,308,674 net of legal and administrative fees of $17,400 and which included a payment of $50,550 for a subscription receivable, under the Company’s common stock purchase agreement with White Lion. · 1,850,000 shares of common stock with a fair value of $462,500 were issued to settle litigation (see Note 8).

Share issuances 2024

During the year ended December 31, 2024, the Company had the following common stock transactions:

	·	5,300,000 shares of common stock were sold for $852,179, net of legal and administrative fees of $11,400, under the Company’s common stock purchase agreement with White Lion.
	·		825,000 units were sold for $66,000. A unit consists of 1 share of common stock and ½ of a warrant and the Company issued 825,000 shares of common stock and 412,500 warrants related to the sale of the units. The Company used the relative fair method in valuing the common stock and warrants included in the sale of the units. The common stock and warrants were valued at $60,010 and $5,990, respectively.

Share issuances 2025

During the year ended December 31, 2025, the Company had the following common stock transactions:

	·	800,000 shares of common stock were sold for $63,308, net of legal and administrative fees of $2,400, under the Company’s common stock purchase agreement with White Lion.
	·		757,031 shares of common stock were issued due to the conversion of convertible notes payable and accrued interest of $53,295.

White Lion Common Stock Purchase Agreement (CSPA)

On September 1, 2022, the Company entered into a common stock purchase agreement (the “CSPA”) with White Lion Capital, LLC (“White Lion”). Pursuant to the CSPA, the Company has the right, but not the obligation, to require White Lion to purchase up to $10,000,000 of the Company’s common stock, subject to certain limitations and conditions set forth in the CSPA. The Company is required to register the resale of the shares issuable to White Lion under the CSPA with the U.S. Securities and Exchange Commission, as a condition to requesting White Lion purchase shares. On September 7, 2022, the Company filed a registration statement on Form S-3 to register for resale up to 15,000,000 common shares. The Company’s S-3 registration statement was declared effective by the SEC on September 19, 2022.

The Company has the right to terminate the CSPA at any time, at no cost or penalty, upon ten trading days prior written notice. Additionally, White Lion will have the right to terminate the CSPA in accordance with its terms for certain breaches of the CSPA by the Company, a Company bankruptcy filing, or the Company’s CEO, Principal Financial Officer or Director of Operations terminating their respective employment with the Company.

On January 25, 2023, the Company and White Lion amended the CSPA (the "First Amendment") to provide that if the Company issues a share price purchase notice at a time that the Company's common stock is trading below the Floor Price and White Lion waives the Floor Price condition, the share purchase price multiplier for that transaction will be 90% instead of 93%.

On June 20, 2024, the Company and White Lion amended the CSPA (the “Second Amendment”) to provide that the purchase price to be paid by White Lion for shares of the Company’s common stock pursuant to the CSPA equals the lower of: (i) 93% of the volume-weighted average price of the Company’s common stock during a period of five consecutive trading days following the Company’s exercise of its right to sell shares (or 95% of that volume-weighted average price if the Company’s common stock is trading on a national exchange), or (ii) the closing price of the common stock on the day the Company exercises its right to sell shares, subject to a floor price of $0.25 per share. The Second Amendment further provides that if the Company issues a share price purchase notice at a time that the Company’s common stock is trading below the floor price and White Lion waives the floor price condition, the purchase price to be paid by White Lion for such shares shall equal 90% multiplied by the lower of the (i) three lowest volume-weighted average price of the Company’s common stock during a period of five consecutive trading days following the Company’s exercise of its right to sell shares, or (ii) most recent closing price of the Company’s common stock prior to White Lion’s receipt of a share price purchase notice.

On June 26, 2024, the Company filed a registration statement on Form S-1 to register for resale an additional 15,000,000 common shares related to CSPA. The Company'’s S-1 registration statement was declared effective by the SEC on July 29, 2024. White Lion’s commitment obligation under the CSPA expired in October 2025.

Alumni Any Market Purchase Agreement

On December 16, 2025, the Company entered into an Any Market Purchase Agreement (“AMPA”) with Alumni Capital, LP (“Alumni”). Pursuant to the AMPA, the Company had the right, but not the obligation, to require Alumni to purchase up to $4,000,000 of the Company’s common stock, subject to certain limitations and conditions set forth in the AMPA. The Company was required to register the resale of the shares issuable to Alumni under the AMPA with the SEC as a condition to requesting that Alumni purchase shares. On January 15, 2026, the Company filed a registration statement on Form S-1 to register for resale up to 25,669,288 common shares, which included shares issuable to Alumni upon exercise of commitment warrants and upon conversion of convertible notes purchased by Alumni under a separate agreement (see Note 5). The Company’s S-1 registration statement was declared effective by the SEC on January 30, 2026. As of April 15, 2026 the Company has not issued any shares to Alumni under the AMPA.

F-14

Table of Contents

Restricted Stock Units

As of December 31, ~~2024~~2025 and December 31, ~~2023~~2024, the Company has 4640,~~165~~315,000 and 4746,~~665~~165,000 restricted stock units (RSU) outstanding, respectively. The RSU’s are subject to certain conditions and shall vest upon the achievement of certain Company objectives and milestones (referred to in the RSU Agreements as Covered Transactions or Triggering Events).

During the year ended December 31, 2024, the Company terminated the services of one of its consultants who had an RSU agreement in place. Per the RSU agreement, all of the unvested RSU’s ~~owed~~held toby the consultant vested immediately upon termination of services. This resulted in 1,500,000 RSU’s vesting and $375,000 of stock-based compensation being recorded which was the fair value of the shares on the original grant date of the RSU agreement.

~~Management~~ During isthe ~~unable~~year toended ~~predict~~December if31, or2025, ~~when~~the aCompany ~~Covered~~terminated ~~Transaction~~the orservices ~~Triggering~~of ~~Event~~one ~~under~~of its consultants who had an RSU agreement in place. Per the RSU ~~Agreements~~agreement, ~~governing~~all of the ~~restricted~~unvested ~~stock~~RSU’s ~~units~~owed ~~will~~to ~~occur~~the ~~and~~consultant asvested immediately upon termination of ~~December~~services. ~~31,~~This ~~2024~~resulted in 975,000 RSU’s ~~there~~vesting ~~was~~and $24692,~~938,630~~250 of ~~unrecognized~~stock-based compensation ~~cost~~being ~~related~~recorded, towhich ~~unvested~~was ~~restricted~~the ~~stock~~fair ~~unit~~value ~~awards~~of the shares on the original grant date of the RSU agreement.

~~Activity~~During ~~related~~the year ended December 31, 2025, the Board of Directors approved an amendment to ~~our~~a ~~restricted~~consultant’s ~~stock~~RSU ~~units~~agreement. The amendment resulted in 3,750,000 of RSU’s vesting during the ~~year~~current ~~ended~~period ~~December~~and 31the remaining 2,750,000 ~~2023~~vesting ~~was~~upon the achievement of certain Company objectives and milestones. Per ASC 718-20-35, the change in vesting conditions resulted in a modification of the stock-based compensation awards. The modification is considered a Type III modification as ~~follows:~~described in ASC 718-20-55 and resulted in recording $427,875 of stock-based compensation expense which was the fair value of the shares on the date of the modification.

	Number of Units		Weighted AverageGrant Date Fair Value
Total awards outstanding at December 31, 2022		47,665,000	$	0.54
Units granted		-	$	-
Units Exercised/Released		-	$	-
Units Cancelled/Forfeited		-	$	-
Total awards outstanding at December 31, 2023		47,665,000	$	0.54

During the year ended December 31, 2025, an officer of the Company resigned from his position. This officer had an RSU agreement in place. Per the RSU agreement, all of the unvested RSU’s owed to the officer cancelled immediately upon resignation. This resulted in the cancelation of 1,125,000 RSU’s and $0 stock-based compensation being recorded.

Activity related to our restricted stock units during the year ended December 31, 2024 was as follows:
				Weighted
				Average
				Grant
	Number of			Date Fair
	Units			Value
Total awards outstanding at December 31, 2023		47,665,000		$	0.54
Units granted		-		$	-
Units Exercised/Released		(1,500,000	)	$	0.25
Units Cancelled/Forfeited		-		$	-
Total awards outstanding at December 31, 2024		46,165,000		$	0.55

Management is unable to predict if or when a Covered Transaction or Triggering Event under the RSU Agreements governing the restricted stock units will occur and as of December 31, 2025, there was $18,834,405 of unrecognized compensation cost related to unvested restricted stock unit awards.

Activity related to our restricted stock units during the year ended December 31, 2024 was as follows:

	Number of Units			Weighted Average Grant Date Fair Value
Total awards outstanding at December 31, 2023		47,665,000		$	0.54
Units granted		-		$	-
Units Exercised/Released		(1,500,000	)	$	0.25
Units Cancelled/Forfeited		-		$	-
Total awards outstanding at December 31, 2024		46,165,000		$	0.55

Activity related to our restricted stock units during the year ended December 31, 2025 was as follows:

				Weighted
				Average
				Grant
	Number of			Date Fair
	Units			Value
Total awards outstanding at December 31, 2024		46,165,000		$	0.55
Units granted		-		$	-
Units Exercised/Released		(4,725,000	)	$	0.24
Units Cancelled/Forfeited		(1,125,000	)	$	0.99
Total awards outstanding at December 31, 2025		40,315,000		$	0.52

F-15

Table of Contents

Warrants

During the year ended December 31, 2024, the Company issued 412,500 warrants related to the sale of 825,000 units. The Company valued the common stock and warrants issued in the sale of the units using the relative fair value method. The warrants have a value of $5,990 and was recorded in additional paid-in capital.

During the year ended December 31, 2025, the Company issued 3,484,321 commitment warrants. The Company valued the commitment warrants using the Black Scholes model. The warrants were initially valued at $169,582 and recorded as a derivative liability.

The Company analyzed the 2025 commitment warrants under ASC 480 Distinguishing Liabilities from Equity and ASC 815 Derivatives and Hedging and concluded that they meet the definition of a liability under ASC 480-10-25. Upon the occurrence of a qualifying Fundamental Transaction, the holder may require the Company to settle the warrant for cash. This feature represents a potential obligation to transfer assets upon an event that is not solely within the Company’s control and therefore constitutes an obligation that is economically equivalent to a written put on the Company’s own equity. The fair value of the derivative liability associated with the commitment warrants is summarized as follows:

Initial grant date valuation (December 16, 2025)	$	169,582
Change in fair value		(28,334	)
Balance at December 31, 2025	$	141,248

Activity related to our warrants during the year ended December 31, 2024 was as follows:

	Number of Warrants		Weighted Average Exercise Price
Total warrants outstanding at December 31, 2023		-	$	-
Granted		412,500	$	0.14
Exercised		-	$	-
Cancelled/Forfeited		-	$	-
Total warrants outstanding at December 31, 2024		412,500	$	0.14

Activity related to our warrants during the year ended December 31, 2025 was as follows:

	Number of Warrants		Weighted Average Exercise Price
Total warrants outstanding at December 31, 2024		412,500	$	0.14
Granted		3,484,321	$	0.07
Exercised		-	$	-
Cancelled/Forfeited		-	$	-
Total warrants outstanding at December 31, 2025		3,896,821	$	0.08

F-16

Table of Contents

The fair value of each warrant on the date of grant is estimated using the Black-Scholes valuation model. The following weighted-average assumptions were used for the warrants granted during the year ended December 31, 2024:

	Year Ended
	December 31,
	2024
Exercise price	$	0.14
Expected term	1 year
Expected average volatility		90.88	%
Expected dividend yield		-
Risk-free interest rate		4.17	%

The ~~following~~fair ~~table~~value ~~summarizes~~of ~~information~~each ~~relating~~warrant toon ~~outstanding~~the ~~and~~date ~~exercisable~~of ~~warrants~~grant and as of each reporting date is estimated using the Black-Scholes valuation model. The following weighted-average assumptions were used for the warrants granted during the year ended December 31, ~~2024~~2025:

Warrants Outstanding										Warrants Exercisable
		Grant Date December 16,2025				December 31,2025
				Weighted Average
Exercise price		$	0.07			$	0.07
Number Warrants				Remaining Contractual				Weighted Average		Number		Weighted Average
Expected term		5 years				5 years
				life (in years)				Exercise Price		of Shares		Exercise Price
Expected average volatility			104.67	%			104.69	%
	412,500				2			$	0.14		412,500	$	0.14
Expected dividend yield			-				-
Risk-free interest rate			3.73	%			3.73	%

~~Aggregate~~The ~~intrinsic~~following ~~value~~table issummarizes ~~the~~information ~~sum~~relating ofto ~~the~~outstanding ~~amounts~~and byexercisable ~~which the quoted market price of the Company’s stock exceeded the exercise price of the~~ warrants atas ~~December 31, 2024. As~~ of December 31, ~~2024, the aggregate intrinsic value of warrants outstanding was approximately $0.~~2025:

F-16 Table of Contents

Warrants Outstanding						Warrants Exercisable
		Weighted Average
Number Warrants		Remaining Contractual		Weighted Average		Number		Weighted Average
		life (in years)		Exercise Price		of Shares		Exercise Price
	412,500		1.00	$	0.14		412,500	$	0.14
	3,484,321		4.96	$	0.07		3,484,321	$	0.07

~~Note~~Aggregate 7intrinsic value is the sum of the amounts by which the quoted market price of the Company’s stock exceeded the exercise price of the warrants at December 31, 2025. ~~Accrued~~As ~~Litigation~~of ~~Settlement~~December 31, 2025, the aggregate intrinsic value of warrants outstanding was approximately $0.

On June 15, 2022, the Security and Exchange Commission’s (SEC) investigation of the Company, initially reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, was settled through the filing of a consent judgment without the Company admitting or denying the SEC’s allegations. As part of the settlement, the Company was required to pay a civil penalty of $450,000, payable in four installments as follows:

· $50,000 upon the entry of the judgment; · $100,000 within 90 days of the entry of the judgment; · $150,000 within 180 days of the entry of the judgment; and · $150,000 within 270 days of the entry of the judgment, plus statutory interest on payments made after 30 days of the entry of the judgment pursuant to U.S.C. Section 1961

During the year ended December 31, 2022 the Company made the initial scheduled payment of $50,000 and the second scheduled payment of $100,000 towards the civil penalty and as of December 31, 2022, the accrued litigation balance was $300,000.

During the year ended December 31, 2023, the Company amended its installment payment plan to the SEC related to its civil penalty. The amended payment plan called for the Company to make three $50,000 payments with payments due on August 1, 2023, September 1, 2023 and October 1, 2023 with any remaining principal plus outstanding post-judgement interest to be paid on November 1, 2023.

During the year ended December 31, 2023, the Company made the remaining payments owed on the civil penalty and paid $7,638 of post-judgement interest. As of December 31, 2023 the accrued litigation settlement balance was $0.

Note 8. Litigation

Effective as of March 31, 2023, a 2018 lawsuit filed by Philip Forman, against the Company and its former CEO relating to the validity of a June 25, 2015 Amendment to his November 10, 2014 Employment Agreement with the Company and claims for compensation on termination of his employment was settled. In the settlement, as full and complete consideration, the Company issued to Mr. Forman 1,850,000 shares of common stock of the Company with a fair value of $462,500.

F-17

Table of Contents

~~As mentioned in~~ Note 7. ~~above,~~Income the Company settled the SEC’s investigation through the filing of a consent judgment on the terms described in the Company’s Form 8-K filed on April 29, 2022, without the Company admitting or denying the SEC’s allegations.Tax

Note 9. Income Tax

The Company accounts for income taxes under the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 740, Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company did not take any uncertain tax positions and had no adjustments to its income tax liabilities or benefits pursuant to the provisions of Section 740-10-25 for the years ended December 31, ~~2024~~2025 and ~~2023~~2024. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. No such interest or penalties were recognized during the period presented. The Company had no accruals for interest and penalties at December 31, ~~2024~~2025 or ~~2023~~2024.

The Company’s federal income tax returns for the years ended December 31, ~~2021~~2022 through December 31, ~~2024~~2025 remain subject to examination by the Internal Revenue Service as of December 31, ~~2024~~2025.

During ~~2024~~2025 and ~~2023~~2024, the Company incurred net losses and, therefore, has no tax liability. The net deferred tax asset generated by the loss carry-forward has been fully reserved.

F-18

Table of Contents

Net deferred tax assets consist of the following components as of December 31, ~~2024~~2025 and ~~2023~~2024:

	2024			2023
	2025			2024
Deferred tax assets:
Net operating loss carryover	$	5,~~310~~617,500		$	45,~~989~~310,~~300~~500
Accrued related party payroll		3724,~~500~~000			1137,~~000~~500
Valuation allowance		(5,~~348~~641,~~000~~500	)		(5,~~000~~348,~~300~~000	)
Net deferred tax asset	$	-		$	-

The income tax provision differs from the amount of income tax determined by applying the U.S federal income tax rate (21%) for the years ended December 31, ~~2024~~2025 and ~~2023~~2024 due to the following:

	2024			2023
	2025			2024
Book income	$	(~~420~~560,~~400~~600	)	$	(~~550~~420,~~900~~400	)
Related party accrued payroll		3724,~~500~~000			1137,~~000~~500
(Gain) Loss on debt settlement		~~(24,200~~-	)		16(24,~~900~~200	)
Stock for services and compensation		78235,~~800~~200			9778,~~100~~800
Interest amortization		-300			~~6,900~~-
Inventory write-off		~~7,100~~-			-7,100
Valuation allowance		321,200			419,000
Other income		(6,000	)		-
Valuation allowance		307,100			321,200
Income tax expense	$	-		$	-

As of December 31, ~~2024~~2025 and ~~2023~~2024, the Company has taxable net loss carryovers of approximately $~~25.5~~27 million and $2325.82 million, respectively that may be offset against future taxable income.

Note 108. Other Income

During the year ended December 31, 2024, the Company entered into a settlement agreement with one of its vendors related to outstanding invoices. The Company paid $55,532 to the vendor related to outstanding invoices of approximately $171,000 resulting in a gain on settlement of $115,085. The gain of $115,085 was recorded as other income in the statement of operations.

~~Note~~During 11the year ended December 31, 2025, the Company paid $242,000 to a private investment firm and fell victim to online fraud resulting in the theft of $242,000 which is recorded as a loss on fraud. The ~~Leases~~loss of $242,000 was recorded as other income in the statement of operations. As part of the same scheme, the Company incurred approximately $8,000 of fees and transaction expenses which were recorded as operating expenses in the statement of operations.

OnDuring ~~October~~the year ended December 31, ~~2022~~2025, the Company ~~signed~~recognized a ~~120-day~~gain ~~lease~~in ~~for~~the ~~600~~change ~~square feet of space~~ in ~~Hammonton,~~the ~~New~~fair ~~Jersey~~market tovalue ~~install~~of ~~and test its medical device equipment. The agreement required $2,500 upon signing~~ the ~~agreement~~derivative ~~and~~liability ~~monthly payments~~ of $228,~~500~~334. The ~~Company~~gain ~~did not renew the lease agreement but used the facility on a month-to-month basis until a new location~~ was ~~found.~~recorded ~~During~~as ~~the~~other ~~year~~income ~~ended~~in ~~December 31, 2023,~~ the ~~Company~~statement ~~paid~~of ~~$10,000 in lease expense related to this lease~~operations.

Note 9. Leases

In May 2023, the Company entered into 36-month operating lease, which provides for approximately 1,800 square feet of office space, that commenced on June 1, 2023 and ends on May 31, 2026. The lease required a $2,850 security deposit and monthly lease payments are $2,850 the first year of the lease, $2,964 the second year and $3,082 the third year. The Company or landlord may terminate the lease at the expiration date by giving to the other party written notice at least ninety (90) days prior to the expiration date. The lease may be renewed for a term of one (1) year.

F-19

Table of Contents

Operating lease right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. On the commencement date of the lease, the Company recorded $92,425 related to the ROU asset and lease liability.

The components of lease expense and supplemental cash flow information related to the lease for the period are as follows:

	Year Ended December 31, 2024			Year Ended December 31, 2023
	Year Ended December 31, 2025			Year Ended December 31, 2024
Lease Cost
Operating lease cost (included in general and administrative in the Company’s statement of operations)	$	3536,~~584~~382		$	2035,~~757~~584
Other Information
Cash paid for amounts included in the measurement of lease liabilities for the year ended December 31, 2024 and 2023	$	34,998		$	19,950
Cash paid for amounts included in the measurement of lease liabilities for the year ended December 31, 2025 and 2024	$	37,078		$	34,998
Weighted average remaining lease term – operating leases (in years)	0.41 years	~~1.41 years~~		1.41 years	~~2.42 years~~
Average discount rate – operating lease		10	%		10	%

The supplemental balance sheet information related to leases for the period is as follows:

	At December 31, 2024		At December 31, 2023
	At December 31, 2025		At December 31, 2024
Operating leases
Remaining right-of-use assets	$	4714,~~096~~574	$	7647,~~520~~096
Short-term operating lease liabilities	$	3315,~~331~~157	$	2833,~~838~~331
Long-term operating lease liabilities	$	~~15,158~~-	$	4815,~~489~~158
Total operating lease liabilities	$	4815,~~489~~157	$	7748,~~327~~489

Maturities of the Company’s undiscounted lease liabilities are as follows:

Year Ending	OperatingLeases
2025	$	36,394
2026	$	15,410
2026		15,410
Total lease payments		15,410
Total lease payments		51,804
Less: Imputed interest/present value discount		(253	)
Less: Imputed interest/present value discount		(3,315	)
Present value of lease liabilities	$	15,157
Present value of lease liabilities	$	48,489

Note 1210. Subsequent Events

The Company has evaluated events from December 31, ~~2024~~2025, through the date whereupon the financial statements were issued and has determined that there are no material events that need to be disclosed~~, except as follows:~~.

The Company ~~issued~~has ~~shares~~evaluated ofthe ~~common~~events ~~stock~~from ~~for~~December 31, 2025 through the date whereupon the financial statements were issued and notes the following subsequent event: On April 13, 2026 the Company issued a promissory note for a principal amount of $70,000. The note carries an interest rate of 15% and matures on July 31, 2026.

· $90,000 of Convertible Notes were issued to accredited investors with a maturity date of December 31, 2026, an interest rate of 13.0% and a $0.12 per share conversion price. In the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.12 per share, the conversion price shall be reduced to equal such lower issue price per share.

F-20

Table of Contents

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company needs to implement disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the ‘‘“Exchange Act’’”), that are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports are recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our Chief Executive Officer and Chief Financial Officer to allow timely decisions regarding required disclosure.

As of December 31, ~~2024~~2025, the Chief Executive Officer and Chief Financial Officer carried out an assessment, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rules 13a-15(b) and 15d-15(b). As of the date of this assessment, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were not effective as of December 31, ~~2024~~2025.

Management’s Report on Internal Control over Financial Reporting

Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with accounting principles generally accepted in the United States of America. Internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the interim or annual financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate.

The Chief Executive Officer ~~and Principal Financial Officer~~ assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, ~~2024~~2025. In performing its assessment of the effectiveness of the Company’s internal control over financial reporting, management applied the criteria described in the Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (‘‘“COSO - 2013’’”).

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

2224 Table of Contents

The material weaknesses identified during management’s assessment were the following:

	·	Inadequate corporate governance

	·	Inadequate internal control structure and control environment

	·	Lack of information technology controls

	·	Lack of segregation of duties

	·	Limited accounting resources with SEC experience, US generally accepted accounting principles knowledge and tax accounting expertise

These material weaknesses could result in a material misstatement of significant accounts or disclosures that would result in a material misstatement to the Company’s interim or annual financial statements that would not be prevented or detected.

Because of the material weaknesses, management concluded that the Company did not maintain effective internal control over financial reporting as of December 31, ~~2024~~2025, based on the criteria in Internal Control-Integrated Framework issued by COSO -2013.

Changes in Internal Control over Financial Reporting

There were no reported changes in internal control over financial reporting for the year ended December 31, ~~2024~~2025.

ITEM 9B. OTHER INFORMATION

None.

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

None.

2325 Table of Contents

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE

Directors and Executive Officers

Our directors and executive officers as of the filing date of this Annual Report on Form 10-K are as follows:

Name	Age	Position with Company
Brian Thom	5960	Chief Executive Officer, Principal Financial Officer and Director
Kristofer Heaton	46	Vice President of Finance and Principal Financial Officer
Robert Denser	54	Director
Robert Denser	53	Director

Our directors hold office for one-year terms and until their successors have been elected and qualified. Our officers are appointed annually and serve at the discretion of the Board.

Directors and Executive Officers

Brian Thom was appointed as Chief Executive Officer effective December 1, 2020 and joined our Board as a Director on January 1, 2021. Mr. Thom has served as a consultant to the Company since April 2020 overseeing finance and business development activities and has served as external financial advisor to the Company since 2018. He brings over 20 years of corporate finance experience and a successful track record of helping fast growing companies across a broad range of industries to raise capital and create shareholder value. Over the course of his career he spent a decade with JPMorgan’s global Mergers and Acquisitions group and five years leading the Americas Corporate Finance group with Société Générale, a multi-national European investment bank, among other entrepreneurial pursuits.

2426 Table of Contents

~~Kristofer~~Robert ~~Heaton~~J. ~~was~~Denser ~~brought~~has onserved as a Director of the ~~Vice~~Company ~~President~~since ofNovember ~~Finance~~2014. Over the past 10 years, his main focus has been to assist federal and ~~Principal~~state ~~Financial~~agencies, ~~Officer~~first inresponders, ~~December~~EMS ~~2020.~~agencies Mrand hospitals with their planning and procurement of the necessary medical equipment needed to be adequately prepared for any type of natural or man-made disaster. ~~Heaton~~This isincludes aworking ~~CPA~~with ~~designation~~the Medical Directors and ~~began~~their ~~his~~teams ~~career~~from inthe ~~commercial~~State ~~banking~~of California and Los Angeles County with the development and fulfilment of a ~~bank~~$60 inmillion ~~Salt~~project ~~Lake~~that ~~City~~will ingive ~~2004~~hospitals the caches of medical equipment needed to properly respond to the surge of patients that will result from a disaster. InFor ~~2006~~the past five years, heMr. ~~moved~~Denser tohas ~~public~~been ~~accounting~~a member of ETL Response, LLC and ~~gained~~has ~~experience~~been in ~~various~~the ~~industries~~role ~~while~~of ~~working~~Director ~~for~~of ~~various~~Sales ~~firms~~and Finance. In this role he coordinates all ETL projects as needed. ETL Response. Mr. ~~Heaton~~Denser’s ~~founded~~background ~~his~~experience ~~own~~also ~~accounting~~includes ~~firm~~direct inaccess ~~2015~~to ~~which~~key ~~specializes~~decision inmakers ~~audits~~within ofthe ~~public~~VA ~~companies~~hospital system, as well as federal and ~~has~~private ~~provided~~disaster ~~non-audit~~response ~~accounting~~agencies, like FEMA and ~~administrative~~the ~~services~~Red toCross, that are on the ~~Company~~front ~~since~~lines ~~2017~~of any disaster.

Robert J. Denser has served as a Director of the Company since November 2014. Over the past 10 years, his main focus has been to assist federal and state agencies, first responders, EMS agencies and hospitals with their planning and procurement of the necessary medical equipment needed to be adequately prepared for any type of natural or man-made disaster. This includes working with the Medical Directors and their teams from the State of California and Los Angeles County with the development and fulfillment of a $60 million project that will give hospitals the caches of medical equipment needed to properly respond to the surge of patients that will result from a disaster. For the past five years, Mr. Denser has been a member of ETL Response, LLC and has been in the role of Director of Sales and Finance. In this role he coordinates all ETL projects as needed. ETL Response. Mr. Denser’s background experience also includes direct access to key decision makers within the VA hospital system, as well as federal and private disaster response agencies, like FEMA and the Red Cross, that are on the front lines of any disaster.

Directors’ and Officers’ Liability Insurance

We are ~~currently~~maintaining ~~seeking to obtain~~ directors’ and officers’ liability insurance against any liability for acts or omissions in their capacities as directors or officers, subject to certain exclusions. Such insurance also ~~would~~insures ~~insure~~ us against losses, which we may incur in indemnifying our officers and directors. In addition, we may enter into indemnification agreements with key officers and directors and such persons shall also have indemnification rights under applicable laws, and our certificate of incorporation and bylaws.

Corporate Governance

Our business, property and affairs are managed by, or under the direction of, our Board, in accordance with the General Corporation Law of the State of Nevada and our By-Laws. Members of the Board are kept informed of our business through discussions with the Chief Executive Officer ~~and other key members of management~~, by reviewing materials provided to them by management.

We continue to review our corporate governance policies and practices by comparing our policies and practices with those suggested by various groups or authorities active in evaluating or setting best practices for corporate governance of public companies. Based on this review, we have adopted, and will continue to adopt, changes that the Board believes are the appropriate corporate governance policies and practices for our Company. We have adopted changes and will continue to adopt changes, as appropriate, to comply with the Sarbanes-Oxley Act of 2002 and subsequent rule changes made by the SEC and any applicable securities exchange.

Director Qualifications and Diversity

The Board seeks independent directors who represent a diversity of backgrounds and experiences that will enhance the quality of the board’s deliberations and decisions. Candidates shall have substantial experience with one or more publicly traded companies or shall have achieved a high level of distinction in their chosen fields. The Board is particularly interested in maintaining a mix that includes individuals who are active or retired executive officers and senior executives, particularly those with experience in the medical device and health care industries.

In evaluating Director candidates, our Board also looks for certain personal attributes, such as integrity, ability and willingness to apply sound and independent business judgment, comprehensive understanding of a director’s role in corporate governance, availability for meetings and consultation on Company matters, and the willingness to assume and carry out fiduciary responsibilities. Qualified candidates for membership on the Board will be considered without regard to race, color, religion, sex, ancestry, national origin or disability.

2527 Table of Contents

Risk Oversight

Enterprise risks are identified and prioritized by management and each prioritized risk is assigned to the full board for oversight. These risks include, without limitation, the following:

	·	Risks and exposures associated with strategic, financial and execution risks and other current matters that may present material risk to our operations, plans, prospects or reputation.

	·	Risks and exposures associated with financial matters, particularly financial reporting, tax, accounting, disclosure, internal control over financial reporting, financial policies, investment guidelines and credit and liquidity matters.

	·	Risks and exposures relating to corporate governance; and management and director succession planning.

	·	Risks and exposures associated with leadership assessment, and compensation programs and arrangements, including incentive plans.

Board Leadership Structure

In accordance with the Company’s By-Laws, the Chairman of the Board presides at all meetings of the Board. Mr. Thom holds the position of Chief Executive Officer and currently is serving as Chairman [Pro Tem]. The Company has no fixed policy with respect to the separation of the offices of the Chairman of the Board and Chief Executive Officer.

Code of Ethics

We have adopted a Code of Ethics within the meaning of Item 406(b) of Regulation S-K of the Exchange Act. This Code of Ethics applies to our directors and senior officers, such as the principal executive officer, principal financial officer and persons performing similar functions. Our Code of Ethics is available as ~~Exhibit~~an 14exhibit to ~~our~~this Annual Report on Form 10-K ~~filed April 16, 2010~~.

Committees

As of the filing date of this Form 10-K, the Board of Directors has no committees. Robert Denser may be deemed an independent director of the Company as that term is defined under Nasdaq Rule 5605(a)(2). Mr. Denser is not deemed to be a financial expert. The term “Financial Expert” is defined under the Sarbanes-Oxley Act of 2002, as amended, as a person who has the following attributes: an understanding of generally accepted accounting principles and financial statements; has the ability to assess the general application of such principles in connection with the accounting for estimates, accruals and reserves; experience preparing, auditing, analyzing or evaluating financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of issues that can reasonably be expected to be raised by the company’s financial statements, or experience actively supervising one or more persons engaged in such activities; an understanding of internal controls and procedures for financial reporting; and an understanding of audit committee functions.

2628 Table of Contents

Insider Trading Policy

The Company has adopted insider trading policies and procedures governing the purchase, sale, and/or other dispositions of its securities by directors, officers and employees, or the Company itself, that are reasonably designed to promote compliance with insider trading laws, rules and regulations, and any listing standards applicable to the Company. Such policies and procedures are ~~filed~~available as ~~Exhibit~~an 19exhibit to this Annual Report on Form 10-K.

Section 16(a) Reports

Section 16(a) of the Securities Exchange Act of 1934 requires our executive officers, directors, and persons who own more than 10% of a registered class of our equity securities, to file with the Securities and Exchange Commission reports of ownership of our securities and changes in reported ownership. Executive officers, directors and greater than 10% beneficial owners are required by SEC rules to furnish us with copies of all Section 16(a) reports they file. The SEC rules require us to disclose late filings of reports of stock ownership and changes in stock ownership by our directors, officers and 10% shareholders. To our knowledge, based solely on our review of (a) the copies of such reports and amendments thereto furnished to us and (b) written representations that no other reports were required, during our fiscal year ended December 31, ~~2024~~2025, all of the Section 16(a) filing requirements applicable to our officers, directors and 10% shareholders have been met.

Communications with the Board of Directors

Stockholders may communicate with the Company’s Board of Directors by sending a letter to United Health Products, Inc., 520 Fellowship Road, Suite #D-406 Mt. Laurel, New Jersey 08054, Attention: Board of Directors. The Company will receive the correspondence and forward it to the Chairman or to any individual director or directors to whom the communication is directed, unless the communication is unduly hostile, threatening or illegal, does not reasonably relate to the Company or its business, or is similarly inappropriate. The Chairman of the Board has the authority to discard or disregard any inappropriate communications or to take other appropriate actions with respect to any such inappropriate communications.

2729 Table of Contents

ITEM 11. EXECUTIVE COMPENSATION

The following table sets forth the overall compensation earned over the fiscal years ended December 31, ~~2024~~2025 and ~~2023~~2024 by (1) each person who served as the principal executive officer of the Company during fiscal year ~~2024~~2025; (2) our most highly compensated (up to a maximum of two) executive officers as of December 31, ~~2024~~2025 with compensation during fiscal year ended ~~2024~~2025 of $100,000 or more; and (3) those individuals, if any, who would have otherwise been included in ~~section~~clause (2) above but for the fact that they were not serving as an executive officer as of December 31, ~~2024~~2025.

Name and Principal Position	FiscalYear	Salary($)~~(4)~~		Bonus($)		Stock Awards($)(1)		Options Awards($)(1)			Non-Equity Incentive Plan Compensation ($)	All Other Compensation($)(2)(3)		Total ($)
Brian Thom	~~2024~~2025	$	198,000	$	-0-	$	-0-	$	-0-	$	-0-	$	-0-	$	198,000
Chief Executive Officer	~~2023~~2024	$	~~253~~198,~~688~~000	$	-0-	$	-0-	$	-0-	$	-0-	$	-0-	$	~~253~~198,~~688~~000
Kristofer Heaton	~~2024~~2025	$	~~165~~74,~~000~~250	$	-0-	$	-0-	$	-0-	$	-0-	$	-0-	$	~~165~~74,~~000~~250
Principal Financial Officer	2023	$	211,406	$	-0-	$	-0-	$	-0-	$	-0-	$	-0-	$	211,406
Former Principal Financial Officer (4)	2024	$	165,000	$	-0-	$	-0-	$	-0-	$	-0-	$	-0-	$	165,000

_____________

(1)

FASB ASC Topic 718 requires the company to determine the overall full grant date fair value of the restricted stock awards and options as of the date of grant based upon the Black-Scholes method of valuation which total amounts are set forth in the table above under the year of grant, and to then expense that value over the service period over which the restricted stock awards and options become vested. As a general rule, for time-in-service-based restricted stock awards and options, the company will immediately expense any restricted stock awards and option or portion thereof which is vested upon grant, while expensing the balance on a pro rata basis over the remaining vesting term of the restricted stock awards and options. For a description FASB ASC Topic 718 and the assumptions used in determining the value of the restricted stock awards and options under the Black-Scholes model of valuation, see the notes to the financial statements included with this Form 10-K.

(2)	Includes all other compensation not reported in the preceding columns, including (i) perquisites and other personal benefits, or property, unless the aggregate amount of such compensation is less than $10,000; (ii) any “gross-ups” or other amounts reimbursed during the fiscal year for the payment of taxes; (iii) discounts from market price with respect to securities purchased from the company except to the extent available generally to all security holders or to all salaried employees; (iv) any amounts paid or accrued in connection with any termination (including without limitation through retirement, resignation, severance or constructive termination, including change of responsibilities) or change in control; (v) contributions to vested and unvested defined contribution plans; (vi) any insurance premiums paid by, or on behalf of, the company relating to life insurance for the benefit of the named executive officer; and (vii) any dividends or other earnings paid on stock or option awards that are not factored into the grant date fair value required to be reported in a preceding column.
(3)		Includes compensation for service as a director described under Director Compensation, below.	~~Includes compensation for service as a director described under Director Compensation, below.~~
(4)		For the year ended December 31, 2023, the amounts include the grant date fair value of $55,688 of stock compensation received in lieu of cash and $66,000 of accrued compensation to Mr. Thom and the grant date fair value of $46,406 of stock compensation received in lieu of cash and $68,750 of accrued compensation for Mr. Heaton.	Mr. Heaton resigned from the positions of Vice President of Finance and Principal Financial Officer of United Health Products effective on June 12, 2025, citing consideration of personal and professional factors.

For a description of the material terms of each named executive officers’ compensation arrangements, including the terms of any contract, agreement, plan or other arrangement that provides for any payment to a named executive officer in connection with his or her resignation, retirement or other termination, or a change in control of the company see section below entitled “Compensation Arrangements.”

No outstanding common share purchase option or other equity-based award granted to or held by any named executive officer were repriced or otherwise materially modified, including extension of exercise periods, the change of vesting or forfeiture conditions, the change or elimination of applicable performance criteria, or the change of the bases upon which returns are determined, nor was there any waiver or modification of any specified performance target, goal or condition to payout, other than as described below.

Compensation Agreements

~~Messrs~~Mr. Thom ~~and~~is ~~Heaton are~~ being compensated at the monthly rate of $16,500 ~~and $13~~,~~750~~ ~~respectively,~~ pursuant to services agreements entered with ~~each of them~~him.

2830 Table of Contents

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END

The following table sets forth all outstanding equity awards held by our named executive officers as of December 31, ~~2024~~2025.

	Option Awards								Stock Awards
Name	Number of Securities Underlying UnexercisedOptions (#)Exercisable		Number of Securities Underlying UnexercisedOptions (#)Unexercisable		Option Exercise Price($)		OptionExpirationDate		Number of Shares or Units That Have Not Vested(#)		Market Value of Shares or Units of Stock That Have Not Vested($) (1)
Brian Thom,		—		—	$	—		—		13,225,000	$	0.43
CEO
Kristofer Heaton,		—		—	$	—		—
Principal Financial Officer										325,000	$	0.71
										400,000	$	1.00
										400,000	$	1.20

_____________

(1)	Market value is based on the stock price on the day the Restricted Stock Unit agreement or amendment was entered into.

Disclosure of Policies and Practices Related to the Grant of Equity Awards Close in Time to the Release of Material ~~Nonpublic~~Non-public Information.

The Company does not have any adopted policies and practices on the timing of equity incentive awards or grants in relation to the disclosure of material ~~nonpublic~~non-public information by the Company. The Company does not have a predetermined schedule as to if or when the Company’s Board of Directors grants or awards equity incentives to the Company’s executive officers, employees or members of the Board of Directors. The Board of Directors takes material ~~nonpublic~~non-public information into account when determining the timing and terms of awards and grants, and whether any disclosure of material ~~nonpublic~~non-public information is timed for the purpose of affecting the value of executive compensation, and will, in these instances, delay the grant of awards if material news is expected to be made public based on discussions with management.

The Company, during the last completed fiscal year, did not award options or other equity incentives to a named executive officer in the period beginning four business days before the filing of a periodic report on Form 10-Q or Form 10-K, or the filing or furnishing of a current report on Form 8-K that discloses material ~~nonpublic~~non-public information, and ending one business day after the filing or furnishing of such report.

DIRECTOR COMPENSATION

The following table sets forth certain information concerning the compensation paid to our directors not named as an executive officer in this Item 11 above for services rendered to us during the fiscal year ended December 31, ~~2024~~2025.

Name

Fees Earned or

Paid in Cash ($)

Stock

Awards (1) (2)

Option

Awards

Total

Robert Denser

—

(1)	FASB ASC Topic 718 requires the company to determine the overall full grant date fair value of the restricted stock awards and options as of the date of grant based upon the Black-Scholes method of valuation which total amounts are set forth in the table above under the year of grant, and to then expense that value over the service period over which the restricted stock awards and options become vested. As a general rule, for time-in-service-based restricted stock awards and options, the company will immediately expense any restricted stock awards and option or portion thereof which is vested upon grant, while expensing the balance on a pro rata basis over the remaining vesting term of the restricted stock awards and options. For a description FASB ASC Topic 718 and the assumptions used in determining the value of the restricted stock awards and options under the Black-Scholes model of valuation, see the notes to the financial statements included with this Form 10-K.

(2)	During the year ended December 31, 2022, the Board of Directors approved an RSU Agreement to grant 1,000,000 RSU’s to Mr. Denser which vest according to certain performance conditions as discussed in the financial statements. The grant date fair value of the RSU’s granted assuming all performance conditions are met would be $430,000.

Cash Fees and Options

Currently the Company has no audit, compensation, corporate governance, nominating or other committee of the Board of Directors. No cash fees have been paid to board members for serving on the board.

2931 Table of Contents

Travel Expenses

All directors are entitled to be reimbursed for their reasonable out-of-pocket expenses associated with attending director and shareholder meetings in person.

Review of Risks Arising from Compensation Policies and Practices

We have reviewed our compensation policies and practices for all employees and concluded that any risks arising from our policies and practices are not reasonably likely to have a material adverse effect on the Company.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

As of March 26, ~~2025~~2026, the Company had ~~252~~258,~~408~~690,~~222~~253 shares of Common Stock outstanding. The only persons of record who presently hold or are known to own (or believed by the Company to own) beneficially more than 5% of the outstanding shares of such class of stock are listed below. The following table also sets forth certain information as to holdings of the Company’s Common Stock of all officers and directors individually, and all officers and directors as a group.

Name and Address of Beneficial Owner (1)	Number ofCommonShares		Percentage
Officers and Directors
Brian Thom		1,054,671	*	*
Robert Denser		1,550,000	*	*
Kristofer Heaton		1,813,729		*
All directors and officers as a group (three persons)		2,604,671		1.0	%
All directors and officers as a group (three persons)		4,418,400		1.8	%
Stockholders
Wendy Beplate Irrevocable Grantor Trust (Trust) (2)		18,000,000		76.19	%

___________

*	Represents less than 1%
(1)	Beneficial ownership is determined in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended, and is generally determined by voting powers and/or investment powers with respect to securities. Unless otherwise noted, all of such shares of common stock listed above are owned of record by each individual named as beneficial owner and such individual has sole voting and dispositive power with respect to the shares of common stock owned by each of them. Such person or entity’s percentage of ownership is determined by assuming that any options or convertible securities held by such person or entity, which are exercisable within sixty (60) days from the date hereof, have been exercised or converted as the case may be, but not for the purposes of determining the number of outstanding shares held by any other named beneficial owner. All addresses for officers and directors are c/o United Health Products, Inc., 520 Fellowship Road, Suite D-406, Mt. Laurel, NJ 08054.
(2)	Based on the Schedule 13D filed by the Wendy Beplate Irrevocable Grantor Trust (the “Wendy Beplate Trust”) with the SEC on December 12, 2024, the Wendy Beplate Trust has a Special Independent Trustee who exercises the sole voting and dipositive control over the Company Common Stock held in the Wendy Beplate Trust. The address of the Wendy Beplate Trust is c/o Suzanna Kolb, 5600 Spalding Drive, Unit 920085, Norcross, Georgia 30010-0085.

Stock Bonuses

The Company paid no stock bonuses during the fiscal years ending December 31, ~~2024~~2025 and ~~2023~~2024.

3032 Table of Contents

Securities Authorized for Issuance under Equity Compensation Plans

The following table shows information, as of December 31, ~~2024~~2025, regarding shares of the Company’s common stock authorized for issuance under its equity compensation plan.

	Number of Securities to be IssuedUpon Exercise of OutstandingOptions, Warrants and Rights (a)			Weighted-Average Exercise Price ofOutstanding Options, Warrants andRights(1)($)(b)		Number of Securities RemainingAvailable for Future Issuance UnderEquity Compensation Plans(Excluding Securities Reflected inColumn (a)(c)
Equity compensation plans not approved by shareholders		4640,~~165~~315,000	(2)		-		475,000	(3)
Equity compensation plans approved by shareholders		-			-		-

(1)	The weighted-average exercise price is calculated based solely on the exercise prices of the outstanding options and do not reflect the shares that will be issued upon the vesting of outstanding RSU awards, which have no exercise price.
(2)	This number includes the following: 4640,~~165~~315,000 shares subject to outstanding awards granted under individual Restricted Stock Unit Agreements, of which no shares were subject to outstanding options and 4640,~~165~~315,000 shares were subject to outstanding RSU awards.
(3)	This number includes 475,000 shares available for issuance under the 2019 Plan,

On August 8, 2013, the Board of Directors approved the 2013 Employee Benefit and Consulting Services Compensation Plan (the “2013 Plan”) which had 15,000,000 shares reserved for issuance under said Plan. The 2013 Plan provided for the direct issuance of shares of common stock and the granting of stock options. No stockholder approval was obtained for this Plan. In September 2013, the Company issued 6,000,000 shares of stock under the 2013 Plan to the Company’s former CEO Douglas Beplate pursuant to his consulting agreement then in effect. No other shares or options have been granted under the 2013 Plan. The 2013 Plan terminated on August 7, 2023.

On October 30, 2019, the Board of Directors approved the 2019 Employee Benefit and Consulting Services Compensation Plan (the “2019 Plan”) which has 2,000,000 shares that may be issued under said Plan. The 2019 Plan provides for the direct issuance of shares of common stock and the granting of non-statutory stock options or incentive stock options on terms established by the Board of Directors or committee thereof. The Plan has not been approved by the Company’s stockholders and this incentive stock options may not be granted under this Plan. The Company approved the issuance of 1,525,000 shares in November 2019 to certain persons who were then consultants, officers and directors. The Company has not issued any options under this 2019 Plan. There are currently 475,000 shares available for issuance under this 2019 Plan.

Separate from the 2013 Plan and 2019 Plan, the Board of Directors approved individual Restricted Stock Unit Agreements with certain consultants, officers and directors (including certain individuals who are now former officers and directors) which represent an unvested aggregate amount of 4640,~~165~~315,000 and 4746,~~665~~165,000 as of December 31, ~~2024~~2025 and ~~2023~~2024, respectively, which upon vesting will result in the issuance of common shares.

3133 Table of Contents

Convertible notes payable

As of December 31, ~~2024~~2025 and ~~2023~~2024, convertible notes payable – related parties (net of debt discount) totaled $500,000 and $500,000, respectively.

During the year ended December 31, 2022, Brian Thom, the Company’s Chief Executive Officer, converted $372,000 of a loan payable balance to a convertible note payable. The unpaid accrued interest on the loan payable was transferred to the convertible note payable. The note had an interest rate of 10%, an original issue discount (“OID”) of 7% and had a maturity date of December 31, 2023. The note is convertible into common stock of the Company at $0.35 per share. In the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.35 per share, the conversion price shall be reduced to equal such lower issue price per share. The Company recorded $28,000 of a debt discount related to the OID. As of December 31, ~~2024~~2025 and December 31, ~~2023~~2024, the remaining unamortized debt discount was $0 and $0, respectively. Accrued interest associated with the note was $~~139~~209,~~334~~447 and $77139,~~287~~334 as of December 31, ~~2024~~2025 and ~~2023~~2024, respectively.

During the year ended December 31, 2022, Robert Denser, a Director of the Company, loaned the Company $93,000 through a convertible note. The note had an interest rate of 10%, an OID of 7% and had a maturity date of December 31, 2023. The note is convertible into common stock of the Company at $0.35 per share. In the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.35 per share, the conversion price shall be reduced to equal such lower issue price per share. The Company recorded $7,000 of a debt discount related to the OID. As of December 31, ~~2024~~2025 and December 31, ~~2023~~2024, the remaining unamortized debt discount was $0 and $0, respectively. Accrued interest associated with the note was $2946,~~315~~126 and $1429,~~438~~315 as of December 31, ~~2024~~2025 and ~~2023~~2024, respectively.

On December 15, 2023, the Company entered into amendments on the above convertible notes, which extended the maturity dates to December 31, 2024 and increased the interest rate from 10% to 13%, effective January 1, 2024. On December 20, 2024, the Company entered into amendments on the above convertible notes, which extended the maturity dates to December 31, 2026.

Interest expense – related party on the above convertible notes payable was $7686,924 (including $0 of debt discount amortization related to the OID) and $7576,~~462~~924 (including $21,669 of debt discount amortization) during the year ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively. Accrued interest – related party due to these convertible notes was $~~168~~255,~~649~~573 and $91168,~~725~~649, as of December 31, ~~2024~~2025 and ~~2023~~2024, respectively.

Note payable – related parties

During the year ended December 31, 2025, the Company’s Chief Executive Officer (CEO) advanced the Company $250,000 to secure a private investment, which is unsecured and non-interest bearing. This note payable was to be repaid from the proceeds of the private investment. In the event that the private investment or similar investment is not completed within 120 days of the execution of this note payable, then the CEO may, at his discretion, demand that the Company commit to apply not less than 25% of the net proceeds of any external capital raising activity (including but not limited to equity placements under any Equity Line of Credit then in effect) towards the repayment of the note payable until it is repaid in full. Any unpaid amounts under this note payable shall be due and payable upon the closing of a sale of all, or substantially, all of the assets of the Company. In addition, any amounts under this note payable unpaid on the seventh (7th) anniversary shall be due and payable one hundred twenty (120) days following demand for payment. As of December 31, 2025, the remaining principal balance due was $250,000.

Loans payable/advances

During the year ended December 31, ~~2022~~2025, ~~Kristofer Heaton,~~ the ~~Principal~~Company’s ~~Financial~~Chief Executive Officer, ~~loaned~~advanced the Company $4145,000 to pay for operating expenses., ~~The~~which ~~loan~~is ~~had~~unsecured, an non-interest ~~rate~~bearing ~~of 10%~~ and ~~was~~ due on demand. During the ~~year~~nine months ended ~~December~~September 3130, ~~2023,~~2025 the Company repaid $4145,000 of ~~principal~~the ~~and~~advance resulting in a $~~446~~0 ofadvance balance recorded in accrued ~~interest~~liabilities ~~leaving~~–related aparties ~~balance~~on ofthe $0balance sheet as of December 31, ~~2023~~2025.

Equity transactions

Director Independence

Management has deemed Robert Denser to be an independent director of the Company as that term is defined under Nasdaq Rule 5605(a)(2).

3234 Table of Contents

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

The following table sets forth the aggregate fees for professional audit services rendered by Mac Accounting Group & CPAs, LLP (“MAC”) for the audit of the Company’s annual financial statements for the fiscal year ended December 31, ~~2024~~2025 and ~~2023~~2024, and fees billed for other services provided by MAC in the fiscal year ended December 31, ~~2024~~2025 and ~~2023~~2024.

	2024		2023
	2025		2024
Audit fees	$	4648,500	$	4946,500
Audit-related fees	$	-	$	-
Tax fees	$	-	$	-
All other fees	$	42,500	$	24,500

Audit Fees consist of the aggregate fees billed for professional services rendered for the audit of our annual financial statements and the reviews of the financial statements included in our Forms 10-Q and for any other services that were normally provided in connection with our statutory and regulatory filings or engagements.

Audit Related Fees consist of the aggregate fees billed for professional services rendered for assurance and related services that were reasonably related to the performance of the audit or review of our financial statements and were not otherwise included in Audit Fees.

Tax Fees consist of the aggregate fees billed for professional services rendered for tax compliance, tax advice and tax planning. Included in such Tax Fees are fees for preparation of our tax returns and consultancy and advice on other tax planning matters.

All Other Fees consist of the aggregate fees billed for products and services provided and not otherwise included in Audit Fees, Audit Related Fees or Tax Fees. Included in such Other Fees are fees for services rendered in connection with any private and public offerings or registration statements conducted during such periods.

Audit Committee Pre-Approval Policy

The Company does not have an audit committee. Audit committee functions are conducted by the Board of Directors. We understand the need for the accounting firm to maintain objectivity and independence in its audit of our financial statements. To minimize relationships that could appear to impair their objectivity, our Board has restricted the non-audit services that they may provide to us.

3335 Table of Contents

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

(1)	Financial Statements

	The financial statements of United Health Products, Inc., supplemental information and report of independent registered public accounting firm are included in this Form 10-K.

(2)	Financial Statement Schedules

Schedules have been omitted because of the absence of conditions under which they are required or because the required information is included in the financial statements or notes thereto.

(3)	Exhibits

	(a)	Exhibits

The following exhibits are filed with this report, or incorporated by reference as noted:

3.1		Articles of Incorporation of the Company dated February 28, 1997 (1)

3.2		Amendment to Articles of Incorporation (1)

3.3		By-laws of the Company (2)

3.4		August 2015 Amendment to Articles of Incorporation (3)

10.1		Services Agreement with Brian Thom (4)

10.2		Restricted Stock Unit Agreement - Brian Thom (4)

10.3		Services Agreement with Kristofer Heaton (5)

10.4		Restricted Stock Unit Agreement - Kristofer Heaton (5)

10.5		Amendment to Restricted Stock Unit Agreement – Brian Thom (6)

10.6		Restricted Stock Unit Agreement – Robert Denser (6)

10.7		Stock Purchase Agreement dated September 1, 2022 between the Company and White Lion Capital LLC (7)

10.8		Amendment to Stock Purchase Agreement dated January 25, 2023 (8)

10.9		Amendment No. 2 to Common Stock Purchase Agreement (9)

19*		Insider Trading Policy

21		Subsidiaries of the Registrant – none

31.1		Certification of Principal Executive Officer*

31.2		Certification of Principal Financial Officer*

32.1		Section 1350 Certificate by Principal Executive Officer*

32.2		Section 1350 Certificate by Principal Financial Officer*

99.1		2019 Employee Benefit and Consulting Services Compensation Plan (10)

3436 Table of Contents

101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).

101.SCH		Inline XBRL Taxonomy Extension Schema Document.

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB		Inline XBRL Taxonomy Extension Labels Linkbase Document.

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

___________

*	Filed herewith.

(1)	Incorporated by reference to the Company’s Form 10-Q for the quarter ended September 30, 2014.

(2)	Incorporated by reference to the Company’s Form 10-Q for the quarter ended June 30, 2022.

(3)	Incorporated by reference to Form 8-K dated August 7, 2015 – date of earliest event filed on August 10, 2015.

(4)	Incorporated by reference to the Form 8-K dated December 2, 2020

(5)	Incorporated by reference to the Form 8-K dated January 11, 2021

(6)	Incorporated by reference to the Form 8-K dated June 23, 2022

(7)	Incorporated by reference to the Form 8-K dated September 1, 2022

(8)	Incorporated by reference to the Company’s Form 10-K for the year ended December 31, 2022

(9)	Incorporated by reference to the Form 8-K dated June 25, 2024

(10)	Incorporated by reference to Form S-8 dated November 1, 2019

3537 Table of Contents

SIGNATURES

Pursuant to the requirements Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	UNITED HEALTH PRODUCTS, INC.
Dated: March 28, 2025	By:	/s/ Brian Thom
Dated: April 15, 2026	By:	/s/ Brian Thom
		Brian Thom
		Chief Executive OfficerPrincipal Executive Officer and Director

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

Signatures		Title	Date
By:	/s/ Brian Thom	Chief Executive Officer, Principal	~~March~~April 2815, ~~2025~~2026
	Brian Thom	Executive Officer and Director
By:	/s/ ~~Kristofer~~Brian ~~Heaton~~Thom	Principal Financial Officer	~~March~~April 2815, ~~2025~~2026
	Kristofer Heaton
	Brian Thom
By:	/s/ Robert Denser	Director	~~March~~April 2815, ~~2025~~2026
	Robert Denser

3638

Filing Compare · United Health Products, Inc.